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ABSTRACT 
 
 
 Several important antifungal drugs inhibit the synthesis of ergosterol, a lipid that 
modulates the thickness, fluidity and permeability of fungal cell membranes. These 
include the azole antifungals, which block ergosterol biosynthesis by inhibiting lanosterol 
demethylase (Erg11p). The resulting depletion of cellular ergosterol and the 
accumulation of ‘toxic’ sterol intermediates are both thought to cause plasma membrane 
dysfunction and ultimately growth arrest. However, the effects of ergosterol depletion 
upon the function of intracellular membranes and organelles are not well described. The 
purpose of this study was to characterize the effects of azole treatment upon the integrity 
of the Candida albicans vacuole, and determine if, in turn, vacuolar trafficking influences 
azole susceptibility.  
 
 Profound fragmentation of the C. albicans vacuole was observed as an early 
consequence of azole treatment, before significant growth inhibition was observed. Using 
a genetic approach, we determined that vacuole fragmentation was a consequence of 
Erg11p inhibition rather than an off-target effect of azole treatment. Moreover, the degree 
of vacuole fragmentation following azole treatment was influenced by Erg3p, an enzyme 
in the ergosterol biosynthetic pathway involved in the production of toxic sterol 
intermediaries upon Erg11p inhibition. 
 
 We also determined that vacuolar trafficking significantly impacts C. albicans 
susceptibility to azole antifungals and other ergosterol biosynthesis inhibitors. For 
instance, a vps21∆/∆ mutant, blocked in membrane trafficking through the pre-vacuolar 
compartment (PVC), grew significantly more than wild-type controls in the presence of 
several azole antifungals under standard susceptibility testing conditions. Furthermore, 
the vps21∆/∆ mutant was able to grow in the presence of the azoles despite depletion of 
cellular ergosterol. This phenotype resembles an exaggerated form of azole tolerance 
known as ‘trailing growth’, which has been described for some clinical isolates. In 
contrast, the vps21∆/∆ mutant is hypersensitive to drugs that block alternate steps in 
ergosterol biosynthesis. 
 
 The azole tolerance phenotype of the C. albicans vps21Δ/Δ mutant was 
independent of known azole resistance mechanisms such as the efflux pumps Cdr1p and 
Mdr1p. Moreover, the azole tolerance of the vps21Δ/Δ mutant was influenced by both pH 
and incubation temperature, consistent with trailing growth phenotypes. The C. albicans 
vps21Δ/Δ mutant exhibits less plasma membrane permeabilization upon azole treatment, 
as determined by the release of a cytoplasmic luciferase reporter into the culture 
supernatant. Our results also reveal that the vps21Δ/Δ mutant has elevated levels of 
intracellular calcium and enhanced calcineurin activity, as evidenced by increased 
expression of a calcineurin responsive RTA2-GFP reporter construct in response to 
fluconazole. Furthermore, the azole tolerant phenotype of the vps21Δ/Δ mutant is 
dependent upon both calcium and calcineurin signaling. These findings underscore the 
importance of endosomal trafficking in determining the cellular consequences of azole 
 vi 
treatment through modulation of intracellular calcium levels and calcineurin dependent 
responses. 
 
 While we determined that deletion of VPS21 alone was not sufficient to confer a 
survival advantage upon C. albicans following azole treatment in the mouse model of 
vaginal candidiasis, the azole susceptibility of the vps21Δ/Δ mutant in the mouse model 
disseminated infection is yet to be tested. Moreover, it is unclear how, or if the azole 
tolerant phenotype of the vps21Δ/Δ mutant relates to that of trailing clinical isolates, or if 
these clinical isolates have abnormal endosomal trafficking. 
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CHAPTER 1.    INTRODUCTION 
 
 
Medical Mycoses 
 
 
Human fungal infections 
 
 An estimated of 1.5 million fungal species exist in nature (1), with only 70,000 
species described so far (2) and around 300 that have been reported to cause disease in 
humans (3). Within the last group, only a few are common pathogens of humans and 
other mammals (2). The latter situation seems to indicate a high degree of resistance of 
mammals to fungi which may be due to both an effective immune system against these 
organisms and an elevated basal body temperature that can be increased upon infection, 
thus limiting the opportunities for development of fungal infections (2). However, over 
the last few decades, fungi have emerged as important public health concerns (4) due to 
the increasing numbers in immunocompromised populations (including those suffering 
from cancer, HIV infection, diabetes, immunosuppressive therapy and cystic fibrosis) (5), 
invasive medical procedures (6) and global environmental changes (2), among other 
factors. In addition, fungi are eukaryotic organisms sisters to animals as part of 
Opisthokonta and hence they share a great number of features with mammalian cells, 
narrowing the number of therapeutic targets that could be exploited to fight fungal 
infections. In this regard, the number of antifungal drugs available remains limited. 
 
 The impact of fungal infections on human health is widely underestimated. Most 
human fungal infections are regarded as opportunistic and are associated with 
predisposing factors that include host immunosuppression, organ transplant, aging, AIDS 
and disruption of the microbiota (7). Human fungal pathogens cause a variety of diseases 
that include cutaneous lesions and acute pulmonary infections in immunocompetent 
individuals and inflammatory and life-threatening infections in immunocompromised 
patients (8). Superficial infections are the most common forms of disease caused by fungi 
and affect ~1.7 billion people worldwide (6). They are characterized as benign and self-
limiting, do not involve tissue invasion and occur on keratinized tissue such as nails, hair 
and outer layers of the skin (9). However, infections of nails and skin can be distressing 
and unappealing, and in many cases the patients can experience pain (10). Common 
examples of superficial fungal infections include athlete’s foot which affects 1 in 5 
adults, and onychomycosis which affects from 5 to 25% of healthy individuals and 
increases its incidence in the elderly (5, 6, 11). This category of fungal infections are 
mostly caused by dermatophytes (mainly Trichophyton spp, Microsporum spp and 
Epidermophyton spp) and to a lesser extent by yeast of the genera Candida spp and 
Malassezia spp, and in fewer cases by molds (9).  
 
 Subcutaneous fungal infections affect the dermis and subcutaneous tissue and 
usually result from invasion by any of several species of fungi after local trauma (12). 
Sporotrichosis (caused by Sporothrix schenkii), mycetoma (caused by Madurella 
mycetomatis, M. grisea, Pseudallescheria boydii among others), and 
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chromoblastomycosis (caused by Fonsecaea pedrosi, F. compacta, Phialophora 
verrucosa, among others) are the most common subcutaneous mycoses. These mycoses 
occur more frequently in tropical and subtropical regions of the planet, where the 
etiological agents are widely distributed in soil, plants and animals (12). As for other 
fungal infections, immunocompromised individuals are at increased risk of developing 
subcutaneous mycoses (12). 
 
 Life-threatening infections are characterized by fungal dissemination to deep 
tissue and internal organs, causing symptoms such as fever and septic shock (5). This 
class of illness occurs in people having well established risk factors that include an 
impaired immunity due to genetic predisposition, neutropenia, immunosuppressive 
therapy and AIDS (5, 6). Although invasive fungal infections occur with lower frequency 
than superficial infections, in immunocompromised individuals they are associated with 
high mortality rates that often exceed 50%, leading to an estimated 1.5 million deaths 
worldwide per year, despite the availability of several antifungal drugs (6). The death toll 
is especially high in settings such as Sub-Saharan Africa where the incidence of 
HIV/AIDS is high and the diagnosis and treatment for invasive fungal infections is 
limited. In addition, the cost of treating systemic fungal infections is high; in the United 
States alone, the annual hospital cost due to invasive fungal infections is estimated to be 
$1.89 billion (13). 
 
 
Etiological agents of invasive mycoses 
 
 Invasive fungal infections in humans can be caused by a wide range of fungi, 
including members of the genera Histoplasma, Coccidioides, Blastomyces, 
Paracoccidioides, Fusarium spp, Sporothrix, Penicillium, Scedosporium, Mucor, 
Rhizopus and Rhizomucor (14-17). However, over 90% of all cases of invasive fungal 
infections are caused by species of Aspergillus, Cryptococcus, Candida and 
Pneumocystis (6, 18, 19). Many of these fungi are widely distributed in nature or are 
considered part of the normal microbiota (e.g., several Candida species), and thus 
controlling the exposure of susceptible patients is impractical. 
 
 Due to the worldwide distribution of Aspergillus, most people breathe its conidia 
(spores) on a daily basis without harmful consequences to the immunocompetent 
populations. However, inhalation of Aspergillus spores can cause invasive infections in 
immunocompromised individuals and those with chronic obstructive pulmonary disease 
(6). Aspergillosis is characterized by the germination of conidia, followed by growth of 
invasive hyphae in the lungs (20). The annual number of cases of aspergillosis is 
estimated to be over 200,000 worldwide, with mortality rates of 50% in patients with 
correct diagnosis and treatment, but it can reach almost 100% if the diagnosis is not 
performed in a timely manner (6). In addition, fungal allergy and A. fumigatus infection 
have been linked to the development of severe asthma (6, 21, 22). Accordingly, the 
global burden of severe asthma due to fungal sensitization is estimated to affect up to 12 
million adults and contribute to the mortality/morbidity due to asthma, which reaches 
over 100,000 cases per year (6, 23). 
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 Cryptococcus is a globally distributed fungal pathogen. After inhalation, 
Cryptococcus spores or desiccated yeast cells enter the respiratory tract where they can 
be eradicated or isolated inside granulomas by the host’s immune response, or cause an 
asymptomatic infection within the lungs (24, 25). However, Cryptococcus cells can 
disseminate hematogenously to other organs including the eyes, urinary tract, bones and 
central nervous system, if host immunity becomes dysfunctional (25). Infection is 
common in patients whose risk factors include AIDS and immunosuppressive therapy 
(6), with mortality rates of 15 to 20% in developed countries and 55 to 70% in Latin 
America and sub-Saharan Africa. For cryptococcal meningitis alone, the annual global 
burden is estimated to be over one million cases, with over 620,000 deaths in sub-
Saharan Africa alone (6, 26) where the access to antiretroviral therapy against HIV/AIDS 
is severely limited. 
 
 A proper and timely diagnosis is imperative to treat invasive fungal infections 
(27). Despite this importance, difficulties in diagnosing these infections remain and 
consequently the high mortality rates of invasive fungal infections (28). The diagnostic 
tools available for fungal infections lack sensitivity and/or have limited specificity (29) 
and access is limited in low income countries (6). Histopathology continues to be a rapid 
and cost-effective means of providing a presumptive or definitive diagnosis of an 
invasive fungal infection; however, it allows only the identification of yeast or molds and 
often lacks enough sensitivity to determine the infecting specie or strain (27, 28). Blood 
and deep-tissue culture are insensitive and slow; for example, blood cultures from 
patients with deep-seated invasive infections often give negative results and blood 
cultures in the diagnosis of invasive candidiasis or aspergillosis have sensitivities of 
~50% and 0%, respectively (6, 18). 
 
 
Candidiasis 
 
 Candida species are normal constituents of the microbiota on the skin, oral cavity, 
gastrointestinal tract and vagina of humans (30). However, in susceptible individuals they 
are the etiological agents of a group of diseases known as candidiasis, that vary from 
superficial mucosal conditions such as oral thrush and vaginitis, to life-threatening 
systemic infections (31). Out of two hundred known Candida species, over a dozen 
species can cause disease in humans, and are collectively considered as the second most 
abundant causes of fungal disease worldwide (6). In terms of incidence in all disease 
manifestations, C. albicans is the leading species among its genera (6). 
 
 Mucosal candidiasis 
 
 Mucosal candidiasis is characterized by profusive growth of Candida on mucosal 
surfaces such as the vagina, esophagus, oropharynx and urinary tracts (5). Excessive 
Candida growth in the oral cavity is known as “oral thrush” and can include infection on 
the mucosa of the mouth and throat. This class of infections is common in 
immunocompromised patients (5); approximately 70% of HIV/AIDS patients develop 
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oropharyngeal candidiasis (32), contributing to a global burden estimated to be around 10 
million annual cases of oral thrush worldwide (6). Vulvovaginal thrush is common in 
otherwise healthy women; it is estimated that 50 to 75% of all women suffer from at least 
one episode of vulvovaginal candidiasis (VVC) in their childbearing years, from which 
40 to 50% will experience a subsequent infection (33). Notably, 5 to 8% of women suffer 
of recurrent VVC, with 3 or more episodes per year (34). Mucosal infections of the oral 
cavity can be unpleasant and uncomfortable when ingesting meals (35), while infections 
of the vaginal tract can cause general discomfort, itching and burning sensation (36). C. 
albicans, C. glabrata, Aspergillus spp., Cryptococcus spp., and Blastomyces spp. among 
other fungi, are able to cause mucosal infections (37). 
 
 Invasive candidiasis 
 
 Invasive candidiasis occurs when any of several Candida species reach the blood 
and organs such as the heart, brain, eyes, and liver, generally due to breach of the 
integument or impaired immune function (38). Several predisposing factors can increase 
the risk of invasive Candida infections and include a severely immunocompromised 
state, the use of catheters, prolonged stays in intensive care units, severe trauma or 
invasive clinical procedures such as major gut surgery or liver transplantation, among 
others (6). Candida species are the most common invasive fungal pathogens with C. 
albicans accounting for more than 50% of all Candida infections (39) and a mortality rate 
of ~46-75% (6, 39). 
 
 Candida bloodstream infection, or candidemia, is the most common form of 
invasive candidiasis with an estimated ~400,000 bloodstream infections occurring 
worldwide per year (6). In the United States, Candida spp. are ranked the fourth most 
common cause of nosocomial bloodstream infections in the intensive care unit (ICU) 
(40). Approximately 10,500 to 42,000 total cases of candidemia are estimated to occur 
annually in the United States (4). Moreover, between 2,800 and 11,200 deaths each year 
may be associated with nosocomial candidemia based on a crude mortality rate of 40% 
for Candida bloodstream infections (4). The annual economic burden for this type of 
infection is estimated to exceed one billion dollars (41). 
 
 
Virulence factors of Candida albicans 
 
 During both mucosal and disseminated infection, C. albicans uses an array of 
virulence attributes that include the ability to switch from yeast to hyphae, and secretion 
of hydrolytic enzymes, among others, that promote host tissue damage (42). 
 
 Hyphal growth 
 
 C. albicans is a polymorphic fungus with the ability to switch reversibly between 
the ovoid-shaped budding yeast, pseudohyphae, and hyphae (43), a process often referred 
as morphogenesis. In the human host, C. albicans can be found as yeast, pseudohyphae or 
in its invasive filamentous hyphal form (30, 43, 44). The morphological plasticity of C. 
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albicans is considered a virulence determinant (45), since the ability to switch between 
both yeast and hyphae have key roles in pathogenesis. In this regard, it is assumed that 
the yeast form is better suited for dissemination to bloodstream and tissues due to its oval 
shape and relatively small size (46), while the hyphal form is better adapted for tissue 
invasion and damage as well as escape from immune cells as hyphae are capable of 
rupturing host cell membranes (45, 47, 48). C. albicans mutants that are unable to form 
hyphae are not only typically avirulent in mouse models of disseminated or mucosal 
candidiasis. They also have decreased ability to invade and damage organs such liver and 
pancreas, have reduced ability to penetrate mucosal surfaces and are also prone to be 
killed by macrophages in vitro (49-52). In addition, strains that are unable to grow in the 
yeast form also have reduced virulence (53, 54), further supporting the importance of the 
ability of C. albicans to transition between yeast and hyphal forms. Importantly, since 
yeast and hyphal cells can both be found in infected organs, with a predominance of one 
particular form depending on the target organ (55), it has been suggested that both have a 
role in disease progression (32). 
 
 Hydrolytic enzymes 
 
 Several enzymes that are secreted by C. albicans have been associated with 
virulence. Among these, secreted aspartyl proteases (SAPs) and phospholipases are the 
best characterized. 
 
 Secreted aspartyl proteases. Aspartyl proteases are proteinases that have two 
highly conserved aspartate residues in the active site that are used to hydrolyze peptide 
bonds in proteins (56). The family of secreted aspartyl proteinases (SAP) in C. albicans 
contains at least ten members between 35 and 50 kDa in size (56-58), whose primary 
function is to degrade proteins for nutrient acquisition (56). SAPs are synthesized as 
preproenzymes that are processed in the Golgi and released into the extracellular space 
via the secretory pathway. They have been linked not only to invasion and damage of 
host tissues, but also to adherence (59); SAPs are able to degrade host membrane proteins 
in order to facilitate invasion (56). This function also seems to confer a protective role 
against the host’s immune system by degrading membrane proteins and proteins secreted 
by the host as part of the immune response against the fungus (56), including lactoferrin, 
immunoglobulins, complement components and cathepsin D (56, 59-61). SAP activity 
can induce an acute inflammatory immune response in the vaginal environment (62) and 
has been shown to lead to activation of the proinflammatory cytokine IL-1β (63). 
 
 Although there are multiple SAPs, the requirement of each one for disease 
development seems to vary between different infection sites. For example, Sap1p-Sap6p 
appear to be required for virulence in models of disseminated candidiasis (64, 65), but the 
requirement of each one of them seems to vary in several in vitro models of mucosal 
disease (66, 67). Sap2 has been shown to be required for disease progression in a rat 
model of vaginal candidiasis (68), and to induce inflammatory responses by itself in a 
mouse model of vaginal candidiasis (62). In addition, several studies have shown a 
positive correlation between the level of SAP activity and virulence of mucosal isolates 
of C. albicans (56, 69-71). Clinical isolates of C. albicans from symptomatic patients 
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with vaginal candidiasis were shown to have higher SAP activity in vitro than isolates 
from asymptomatic patients (69, 70, 72), as did clinical isolates from HIV-positive 
patients with oral candidiasis versus isolates from HIV-negative patients. 
 
 Phospholipases. Phospholipases are enzymes that hydrolyze acyl and phosphate 
esters in phospholipids. In C. albicans phospholipases have been associated with 
penetration and damage of host tissue by degradation of the host’s cell membrane 
phospholipids (73). Several types of phospholipases, including phospholipase A1, A2, C, 
and D, lysophospholipase, and lysophospholipase-transacylase, have been identified in C. 
albicans (74, 75). However, phospholipase B1 (Plb1p) is the only phospholipase that has 
been shown to be required for virulence in vivo. Deletion of PLB1 led to attenuation of 
virulence in a mouse model of disseminated (73) and intragastric candidiasis (76). 
Moreover, Plb1p has been detected at the hyphal tips during penetration of tissues (77). 
 
 
Current Antifungal Therapies 
 
 A large number of fungal pathogens can cause disease in humans, each of them 
with different susceptibilities to the antifungal drugs available. Of concern is that current 
antifungal therapies have led to only modest success in reducing the high mortality rates 
caused by invasive fungal infections, in part due to drug toxicity, narrow spectrum of 
activity and drug resistance (6). In addition, the difficulties in providing a timely and 
accurate diagnosis of invasive fungal infections further limits the chances of reducing 
those mortality rates by delaying the selection of appropriate treatments (78). 
 
 
Ergosterol biosynthesis inhibitors 
 
 A number of enzymes in the ergosterol biosynthetic pathway (Figure 1-1A) are 
targeted by several classes of antifungal drug currently in clinical use; these include the 
morpholines, allylamines and azoles. The membrane lipid ergosterol (Figure 1-1B), the 
primary fungal sterol, is important to modulate the thickness, fluidity and permeability of 
cellular membranes (79, 80). Ergosterol is crucial for cellular processes such as 
sporulation, pheromone signaling and plasma membrane fusion and also contributes to 
the correct function of a wide variety of membrane-bound proteins (81). The function of 
a multitude of proteins including those responsible for nutrient uptake requires ergosterol 
(82). In addition, ergosterol is a major component of secretory vesicles in Saccharomyces 
cerevisiae. Loss of ergosterol in the plasma membrane leads to defects that include loss 
of fluidity and function that in turn inhibits cell growth and cell division (83). Genetic or 
pharmacological inhibition of ergosterol biosynthesis can also impact mitochondrial 
morphogenesis and function in yeast. Several ergosterol biosynthetic (erg) mutants have 
aberrant mitochondrial morphologies and a number of ergosterol biosynthesis inhibitors 
are known to induce reactive oxygen species (ROS) and reduce mitochondrial ATPase 
activity (84-86). Moreover, deletion of the genes responsible for early steps in ergosterol 
biosynthesis in fungi is lethal, underscoring the importance of the synthesis of this lipid 
(87).  
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Figure 1-1. Ergosterol biosynthesis pathway. 
(A) A linear model of the ergosterol biosynthetic pathway is depicted. The enzymes that 
catalyze each step and the intermediates produced (boldface) are shown. The classes of 
antifungals that block the ergosterol biosynthetic pathway and their targets are displayed 
in red. (B) The structures of ergosterol (left) and its functional analog in animal cells 
cholesterol (right) differ from each other by two double-bonds and a methyl group at 
C24. 
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 Morpholines 
 
 The morpholine antifungals, which include the topical amorolfine and the 
agricultural pesticides tridemorph and fenpropimorph, inhibit two enzymes within the 
late ergosterol biosynthetic pathway, sterol-Δ7-Δ8-isomerase and sterol-Δ14-reductase, the 
products of the ERG2 and ERG24 genes, respectively (Figure 1-1A) (88). Growth 
inhibition by these drugs is believed to be the result of the accumulation of sterol 
precursors in the fungal cell and/or the depletion of the major fungal sterol ergosterol 
(88). In vitro susceptibility testing indicates that amorolfine has higher efficacy against 
dermatophytes and dimorphic fungi. However, when tested in animal models of fungal 
infections, amorolfine only showed activity in animal models of dermatophytosis and 
vaginal candidiasis (89).  
 
 Allylamines 
 
 Allylamines inhibit the product of the gene ERG1, squalene epoxidase, which 
catalyzes the epoxidation of squalene to 2,3-oxidosqualene (Figure 1-1A) (90). The 
resulting squalene accumulation and ergosterol depletion affect the integrity of the 
plasma membrane and increases cell permeability, which ultimately leads to growth 
inhibition and cell death (90). This group of drugs includes terbinafine and naftifine. 
Terbinafine, is routinely used in the treatment of nail infections (83). 
 
 Azoles 
 
 The azoles are the most widely used and important class of antifungal drugs, 
which inhibit lanosterol-14-demethylase (Erg11p, Figure 1-1A), a cytochrome P450 
enzyme (81). A nitrogen atom in the azole ring binds to the iron atom in the heme group 
of the active site (91). Inhibition of Erg11p leads to the accumulation of 14α-methylated 
sterol intermediates that are converted by Erg3p to 14α-methylergosta-8,24(28)-dien- 
3β,6α-diol, which accumulates in the plasma membrane resulting in increased 
permeability, defective membrane fluidity and ultimately growth inhibition (92). 
 
 The azoles can be divided into two groups based on the number of nitrogen atoms 
in the azole ring. Imidazoles contain two nitrogen atoms while triazoles contain three 
(Figure 1-2A and B) (5, 93). Imidazoles were the first subclass to be developed for 
antifungal therapy. Several imidazoles such as miconazole (Figure 1-2B, left) and 
clotrimazole have been shown to possess additional mechanisms in addition to Erg11p 
inhibition that mediate their antifungal activity, including direct membrane damage at 
high concentration, inducing ROS production, actin cytoskeleton damage and impairment 
of ATP production. These additional mechanisms may explain why several imidazoles 
are cidal at high concentrations. Although effective antifungals, the elevated toxicity of 
imidazoles when administered orally or parentally restrict their use to topical 
applications. In addition, several of them have poor intestinal absorption, cannot cross the 
cerebrospinal barrier and cause severe side effects including liver and gastrointestinal 
complications. These shortcomings led to the development of the triazoles. The first 
triazole available for clinical use was fluconazole (Figure 1-2B, right) in 1990. It is   
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Figure 1-2. Structure of azole antifungals. 
(A) Azole antifungals are classified with regard to the number of nitrogen atoms in the 
azole rings: imidazoles (left) contain two nitrogen atoms while triazoles (right) contain 
three nitrogen atoms in the azole ring. (B) The chemical structure of the imidazole drug 
miconazole (left) and the triazole antifungal fluconazole (right). 
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highly soluble in water favoring its oral and parenteral use, has good intestinal 
absorption, can cross the blood-brain barrier and has a broad spectrum of activity against 
several groups of fungi. Although the triazoles have proven efficacy with good safety 
profiles, azole resistant fungi have emerged from their continuous use (94). 
 
 The third generation of azole antifungals, also called the “second-generation” 
triazoles, was developed in order to overcome the limitations of the “first-generation” 
triazoles, which included limited spectrum of activity, acquired resistance and toxicity 
among others. Examples of third-generation triazoles include voriconazole, ravuconazole 
and posaconazole, which possess increased potency, wider spectrum of activities, better 
safety profiles, and they represent new alternatives against invasive fungal infections 
such as aspergillosis in immunocompromised populations (93, 95). 
 
 Polyenes 
 
 Polyenes antifungals include amphotericin B (AmB), natamycin and nystatin. 
Polyenes bind directly to plasma membrane ergosterol (Figure 1-1A and B), with a 
secondary mechanism that consists of the formation of channels in the plasma membrane 
that enhances cell killing (96-99) due to leakage of ions and loss of the proton gradient 
(100, 101). In addition, polyenes are able to cause inhibition of plasma membrane chitin 
synthase at high concentration (102). Polyenes are effective against a multitude of fungal 
pathogens that include Candida, Aspergillus, Zygomycetes, Cryptococcus and other 
dimorphic species (102). However, polyenes are also able to bind the ergosterol analog 
cholesterol (Figure 1-2B) on human cell membranes, which explains to a certain extent 
its toxicity (103). For instance, AmB is highly toxic when administered systemically, 
with renal impairment as the main side effect (102, 104). 
 
 
Other antifungals 
 
 Another class of antifungals of clinical importance consists of the echinocandins. 
These drugs are non-competitive inhibitors of the enzyme 1,3-β-D glucan synthase, 
responsible for the synthesis of β-1,3-D-glucan, a polysaccharide important in 
maintaining the structure and integrity of the fungal cell wall as well as cell growth of 
fungi (105, 106). Inhibition of 1,3-β-D glucan synthase leads to the formation of 
defective cell walls that prevent the fungal cells from maintaining shape and which lack 
the rigidity required to tolerate osmotic pressure, thus resulting in cell lysis of yeast (106) 
and the formation of aberrant hyphae in molds (107). 
 
 This class of drugs includes caspofungin and micafungin, which are used 
clinically against Candida and Aspergillus, but have no activity against Cryptococcus, 
Trichosporon, Pseudallescheria, Alternaria, Zygomycetes, Fusarium and other fungi 
(106, 108-111). In addition, they are expensive, only available as intravenous 
formulations, and acquired resistance has been reported (112). 
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Clinical Azole Resistance 
 
 The development of resistance to the azoles is a problem of increasing medical 
significance. The extensive use of fluconazole in the previous two decades has fostered 
the emergence of several intrinsically resistant Candida species such as C. glabrata and 
C. krusei (113), and the development of acquired resistance in C. albicans and other 
fungal species (114-116). In addition, a high level of resistance toward azoles is also well 
known for C. inconspicua, C. rugosa, and C. norvegensis (117). The overall resistance in 
clinical isolates of Candida spp. to fluconazole and voriconazole is ~3-6%, and the level 
of resistance has remained constant over a decade (118). However, a recent report 
revealed clinical azole resistance in 12.5 - 18.8% of C. albicans isolates, 10.2–13.6% of 
C. tropicalis and up to 25% of C. glabrata. (118). Likewise, triazole resistance in 
Aspergillus fumigatus is increasingly being recognized with up to 6% of clinical isolates 
were resistant (119). Furthermore, concern has been expressed over the possibility of 
selection for resistance in opportunistic fungi such as Aspergillus spp. in the environment 
as azole fungicides are widely used in agriculture (120). Hence the development of 
environmentally azole resistant fungi may represent a source of cross-resistant isolates in 
the clinics. 
 
 
Mechanisms of resistance to azole antifungals in Candida albicans 
 
 Microbiological drug resistance can be defined as the reduced susceptibility, or 
lack thereof, to a particular antifungal during in vitro susceptibility testing observed when 
the minimum inhibitory concentration (MIC) of such drug surpasses the established 
susceptibility breakpoint for a fungal species (107). On the other hand, clinical resistance 
can be defined as the inability to eliminate a fungal infection using an antifungal that is 
known to possess in vitro and in vivo activity against a particular species (107). 
 
 Fungal drug resistance can be intrinsic or acquired. The first is an innate property 
of a fungal species and occurs without previous exposure to the drug, and it is 
exemplified by fluconazole resistance in C. krusei and echinocandin resistance in 
Cryptococcus neoformans. Acquired resistance develops after drug exposure and is 
exemplified by the development of resistance to azoles in C. albicans (107). 
 
 Several acquired mechanisms of azole resistance have been characterized in C. 
albicans and usually appear in a stepwise manner (81). These include overexpression and 
mutations within the ERG11 gene and overexpression of efflux pumps, such as Cdr1p 
and Mdr1p. However, a combination of the above mechanisms is usually necessary to 
confer a significant reduction in azole susceptibility (121), and notably, the resistance of 
many fungal isolates is not fully accounted for by any of the mechanisms described so far 
(122). Thus, it is imperative to understand the mechanisms of azole resistance and 
tolerance in order to devise therapeutic strategies to enhance their efficacy, overcome 
drug resistance and extend their span of clinical use. Additionally, accurate interpretation 
of azole susceptibility testing of fungal isolates is a central component of patient 
management. However, this can be complicated by phenomena such as trailing growth 
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(123, 124), which is observed in Candida spp. in vitro during standard susceptibility 
testing. Trailing growth occurs when a clinical isolate appears to be sensitive to azole 
treatment after 24 hours of drug exposure but appear to be resistant at 48 hours (123). 
Yet, the molecular basis as well as the clinical and biological relevance of the trailing 
growth phenomenon remains unclear. 
 
 Azole resistance mechanisms described for C. albicans can be grouped into three 
main categories: decreased intracellular drug accumulation, changes in the target enzyme 
for the drug, and alteration in sterol biosynthesis. 
 
 Decreased intracellular drug accumulation 
 
 The main mechanism contributing to reduction in the accumulation of azole 
antifungals within the fungal cell is increased drug efflux (81) as result of overexpression 
of efflux pumps that extrude azoles back into the extracellular environment (Figure 1-3). 
Early studies on these mechanisms of azole resistance in clinical isolates of C. albicans 
highlighted the elevated mRNA expression of members of the ATP-binding cassette 
(ABC) superfamily and major facilitator superfamily (MFS) (125). The ABC and MFS 
transporters are membrane-bound proteins that use the energy generated from ATP 
hydrolysis or the proton gradient, respectively, to move a wide variety of compounds 
across membranes, including drugs, sugars, and amino acids, among others (126, 127). 
Remarkably, the prevalence of efflux pumps as a mechanism of azole resistance appears 
to be high; Perea et al (128) found that 85% of azole resistant isolates evaluated exhibited 
elevated expression of the genes encoding for efflux pumps. 
 
 In C. albicans, overexpression of CDR1 and CDR2 encoding efflux pumps 
belonging to the ABC transporter family has been associated with cross-resistance to 
azoles and amorolfine (125, 129). Although more CDR genes have been identified (81, 
129, 130), their role in azole resistance is unclear. 
 
 It has been shown that increased CDR1, CDR2 and MDR1 mRNA levels in 
clinical isolates are the result of increased transcription of their respective genes (130). 
This is often a consequence of gain of function mutations in the genes encoding the 
transcription factors Tac1p (131) (which regulates CDR1 and CDR2) and Mrr1p (132) 
(which regulates MDR1) (133), leading to hyperactivity of the transcription factor and the 
overexpression of the target genes. 
 
 Changes in the target enzyme 
 
 The transcription of several genes involved in ergosterol biosynthesis, including 
ERG9, ERG1, ERG7, ERG11, ERG25 and ERG3 is upregulated following treatment with 
azole antifungals in susceptible isolates of C. albicans, presumably as a response to 
depletion of ergosterol and changes in cellular sterol composition (81, 134). However, 
increased expression of ERG11 has been shown to be associated with azole resistance in 
a number of matched sets of susceptible and resistant clinical isolates (Figure 1-3) (125, 
128). Another study showed that 35% of azole resistant isolates were found to have   
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Figure 1-3. Azole resistance mechanisms in fungi. 
(A) Several mechanisms that contribute to azole resistance have been identified in 
pathogenic fungi. (A) Overexpression of the target enzyme lanosterol demethylase 
(Erg11p) allows for the replacement of azole-inhibited proteins. (B) Mutations within the 
ERG11 gene lead to amino acid susbtitutions in the enzyme (mutErg11p) that can reduce 
affinity for the drug. (C) Overexpression of multidrug transporters such as Cdr1p and 
Mdr1p result in reduced accumulation of the azoles within the fungal cell. (D) Mutations 
in genes of the ergosterol biosynthetic pathway, such as ERG3, which result in loss of 
function allows fungi to survive azole exposure by avoiding the production of toxic sterol 
intermediaries that otherwise accumulate in the plasma membrane. 
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elevated ERG11 mRNA levels compared to susceptible isolates (128). The transcription 
factor Upc2p regulates the expression of ERG11 (135, 136). Overexpression and gain of 
function mutations within UPC2 have been shown to be associated with azole resistance 
(135). Activating mutations in UPC2 can lead to constitutive overexpression of ERG11 
and hence, contribute to azole resistance (137, 138). 
 
 In addition, point mutations within ERG11 leading to amino acid substitutions 
around the active site of the enzyme have been linked to azole resistance by reducing the 
affinity of Erg11p for the drug (Figure 1-3) (139). Events of gene conversion leading to 
the selection for allelic variants that confer resistance under selective pressure have been 
reported (83, 140).  
 
 Alterations in the sterol biosynthetic pathway 
 
 Azole treatment leads to the accumulation of 14α-methylergosta-8,24(28)-dien- 
3β,6α-diol, which is believed to be a toxic sterol byproduct of Erg3p activity 
accompanying Erg11 inhibition and has been directly linked to the antifungal activity of 
azoles (141). However, certain azole resistant clinical isolates accumulate 14α-
methylfecosterol following azole treatment instead of the toxic sterol, suggesting loss of 
Erg3p function (142). This alternative sterol allows C. albicans to overcome growth 
inhibition otherwise caused by azoles. Thus, mutations that abolish Erg3p activity are 
regarded as a mechanism of azole resistance (Figure 1-3) (142). 
 
 
Fungal azole tolerance 
 
 The static nature of the azoles allows for fungal cells to persist even at high 
concentrations of the drugs. Azole tolerance is defined as the persistent growth of a 
fungal strain at concentrations above the MIC. A well-known example of azole tolerance 
is the trailing growth phenomenon that is observed during azole susceptibility testing of 
C. albicans isolates. Trailing isolates appear to be susceptible to azole treatment in vitro 
at 24 hours; however, by the 48 hour time-point, they appear to be resistant to azole 
treatment (143). This phenotype is commonly observed when evaluating susceptibility to 
triazole drugs such as fluconazole and itraconazole (123). However, experiments 
performed in mouse models of disseminated infection indicate that C. albicans trailing 
isolates are susceptible to azole treatment in vivo (143-145).  
 
 Several mechanisms have been linked to azole tolerance in fungi. The best studied 
mechanisms of azole tolerance are related to calcium dependent signaling, mainly 
through the calcineurin signaling pathway (146, 147). Calcineurin is a Ca2+ and 
calmodulin dependent serine/threonine protein phosphatase that links Ca2+-dependent 
signaling to a multitude of cellular processes (148). Pharmacological or genetic inhibition 
of calcineurin signaling sensitizes several pathogenic fungi to azole exposure (147, 149). 
For example, combination of fluconazole and cyclosporine A (a cyclophilin inhibitor) or 
FK506 (a FKBP inhibitor) has synergistic effects in that addition of CsA or FK506 
enhance the antifungal efficacy of fluconazole (149, 150). Moreover, deletion of genes 
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encoding for upstream and downstream elements of the calcineurin signaling pathway, 
such as the transcription factor Crz1p (151, 152) or the chaperone Hsp90p (153), 
increases fungal killing by azole treatment. Furthermore, several proteins involved in 
maintenance of calcium homeostasis have been shown to be required for the survival of 
several fungi to azole treatment, as deletion of the genes encoding for such proteins 
enhance the antifungal effects of the azoles (146). These include the plasma membrane 
calcium channel formed by Cch1p and Mid1p (154). 
 
 
Vacuolar Function in Candida albicans 
 
 Within the fungal cell, the vacuole is one of the largest organelles (155). While 
the functions of this acidic membrane-bound compartment have been defined using the 
model S. cerevisiae (49, 156), the findings have been extrapolated to pathogenic fungi 
and is used as a model for the mammalian lysosome. These functions include degradation 
of macromolecules for the recycling of their building blocks, metabolite storage, stress 
tolerance, ion homeostasis and response to starvation in yeast (156). 
 
 An important feature of the vacuole is that many of its functions depend on 
maintaining an acidic lumen (157), a task that depends on the activity of the vacuolar H+-
ATPase (V-ATPase), an enzyme complex responsible for the establishment of a proton 
gradient across the vacuolar membrane driven by ATP hydrolysis (158). For example, 
amino acid storage within the vacuole relies on the proton gradient and activity of at least 
eight H+/amino acid exchangers in the vacuolar membrane (156). The main amino acids 
found to be stored in the vacuole through this system are arginine, lysine, histidine, 
phenylalanine, tryptophan, tyrosine, glutamine, asparagine, isoleucine and leucine (156). 
 
 The vacuole is also the major site of storage of Ca2+ in the fungal cell. Ca2+-
dependent signaling requires the maintenance of low levels of this ion in the cytosol 
under resting conditions (159). The initiation of Ca2+ signals entail its release from 
intracellular stores and influx from the extracellular media in response to different 
stimuli, followed by efflux from the cell and storage back into organelles until resting 
levels are achieved (160). Importantly, several Ca2+ pumps and channels involved in this 
process are located on the vacuolar membrane and include the pump Pmc1p, the Ca2+/H+ 
exchanger Vcx1p and the channel Yvc1p (160, 161). 
 
 Furthermore, the vacuole works as a site of storage for polyphosphate. This 
macromolecular anion serves in amino acid and cation retention. It is also important for 
storage of inorganic phosphate and pH regulation (156). Remarkably, more than 90% of 
cellular Ca2+ is associated with large chains of polyphosphate inside the vacuole (161). 
 
 The vacuole also functions as a storage of alkali metals such as K+ and Na+ and it 
is important to maintain a high K+/Na+ ratio in the cell (159). This process also depends 
on the proton gradient created by the V-ATPase and the activity of the cation/H+ 
antiporter Vnx1p (162). The vacuole is also important for detoxification of metal ions. 
Accumulation of ions such as Cd2+, Co2+ and Cu2+ at high concentrations in the 
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cytoplasm is toxic, but they can be sequestered in the vacuole using a proton gradient 
dependent mechanism (163, 164). On the other hand, Fe2+ can also be sequestered in the 
vacuole via a mechanism independent of vacuole acidification (165). 
 
 Mutants of S. cerevisiae and C. albicans with severe vacuolar dysfunction are 
hyper-susceptible to osmotic stress (156). This includes mutants with defects in protein 
sorting, polyphosphate formation, acidification, vacuole biogenesis, ion regulation, and 
homeostasis of several amino acids (156). 
 
 In C. albicans and other pathogenic fungi, the vacuole plays a pivotal role in 
pathogenesis. Vacuolar defects result in several pathogenesis related phenotypes, 
including susceptibility to a wide variety of stresses and loss of virulence-associated traits 
(49, 51, 166). Vacuolar expansion has been shown to be important for the migration of 
cellular material during hyphal formation, while regulation of vacuolar fragmentation and 
fusion help control cell size and branching (167, 168). Moreover, C. albicans mutants 
with severe vacuolar defects have reduced rates of planktonic growth (49), have reduced 
capacity to form hyphae and are unable to kill phagocytes, a virulence attribute important 
during invasion of host tissue and escape from immune cells (49, 166). In addition, 
several mutants with altered vacuolar function fail to cause disease in a mouse model of 
disseminated candidiasis (51, 166). Mutants severely affected in vacuole biogenesis are 
not only unable to kill systemically infected mice but are also rapidly cleared from the 
target organs (51). 
 
 Recent evidence points to an important role of ergosterol in vacuolar function. 
Ergosterol has been shown to be required for endocytic trafficking to the vacuole (169) 
and for the priming step during homotypic vacuole-vacuole fusion in S. cerevisiae (170). 
In addition, several non-essential S. cerevisiae ergosterol biosynthetic mutants have a 
fragmented vacuole morphology (170, 171). Furthermore, C. albicans mutants lacking 
Erg2p or Erg24p have impaired vacuolar function and were avirulent in a mouse model 
of disseminated candidiasis (172). Yet, the consequences of treatment with ergosterol 
biosynthesis inhibitors of clinical importance upon vacuolar function and the contribution 
of vacuole dysfunction to their antifungal activity remain to be fully understood. 
 
 
Research Hypothesis 
 
 The membrane lipid ergosterol is the most common target of several classes of 
antifungals. It has been widely assumed that both the depletion of cellular ergosterol and 
the accumulation of 'toxic' sterol intermediates in the plasma membrane account for the 
antifungal activity of ergosterol biosynthesis inhibitors (92). Nonetheless, the cellular 
pathways affected by ergosterol depletion remain poorly understood (87). Moreover, it 
remains unknown whether the antifungal activity of the azoles is only due to plasma 
membrane dysfunction, or if it is compounded by the dysfunction of other intracellular 
membranes.  
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 Although the bulk of cellular ergosterol is found in the plasma membrane, other 
intracellular membrane compartments such as the fungal vacuole also contain ergosterol 
(87, 173). Thus it is likely that the function of other intracellular membranes is 
profoundly impacted by ergosterol availability following treatment with ergosterol 
biosynthesis inhibitors. 
 
 In a high-throughput screen for compounds that target the fungal vacuole, several 
azole antifungals were identified as causing disruption of this organelle in C. albicans 
(unpublished results). After considering the importance of the vacuole in C. albicans 
biology, I hypothesize that disruption of vacuolar integrity contributes to the antifungal 
activity of the azoles and, in turn, vacuolar dysfunction can impact the antifungal efficacy 
of this class of drugs. 
 
 
Research Objectives 
 
 In order to address the research hypothesis, I have established 4 research 
objectives: 
 
• To characterize the effects of azole treatment upon the integrity of the C. albicans 
vacuole (Chapter 2). 
 
• To determine if membrane trafficking to the vacuole affects susceptibility to azole 
antifungals (Chapter 3). 
 
• To determine the mechanisms by which a C. albicans mutant lacking the Rab 
GTPase Vps21p is tolerant to azole antifungals (Chapter 4). 
 
• To study the interactions between endosomal trafficking and known mechanisms 
of azole resistance (Chapter 5). 
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CHAPTER 2.    THE AZOLE ANTIFUNGALS SEVERELY DISRUPT 
VACUOLAR INTEGRITY IN CANDIDA ALBICANS THROUGH INHIBITION 
OF ERG11P* 
 
 
Introduction 
 
 Several of the most successful antifungal therapies currently used in both the 
clinical and agriculture settings target the biosynthesis of the membrane lipid, ergosterol. 
Azoles are the most important class of antifungals; they inhibit ergosterol biosynthesis by 
preventing the function of lanosterol-14α-demethylase (Erg11p), which in turn causes 
plasma membrane damage, presumably as a consequence of both ergosterol depletion and 
the accumulation of toxic sterol intermediaries. Ergosterol is the major sterol in fungal 
cell membranes, and plays an essential role in maintaining and regulating plasma 
membrane integrity, fluidity and permeability. In addition, ergosterol is also required for 
the normal function of a number of plasma membrane proteins, including several proteins 
involved in nutrient uptake at the plasma membrane such as the tryptophan permease 
Tat2p (82) and the amino acid permease Gap1 (174), the activity of chitin synthase (175, 
176), and the association of beta-1,3-glucanosyltransferase Gas1p and Pma1p with lipid 
rafts (177). Accordingly, ergosterol is required for several biologically important cellular 
functions including cellular signaling (178), sporulation in S. cerevisiae (179), as well as 
polarized hyphal growth in C. albicans (180). 
 
 The bulk of cellular ergosterol is found in the plasma membrane. As such, it is 
widely assumed that the primary consequence of ergosterol depletion, and the 
accumulation of sterol-diol following azole treatment is plasma membrane dysfunction. 
However, other intracellular membrane compartments like the mitochondria, 
endoplasmic reticulum, trans-Golgi network and the fungal vacuole, are also known to 
contain smaller amounts of ergosterol (87, 173). Thus it is likely that the function of other 
intracellular membranes is profoundly impacted by ergosterol availability following 
treatment with ergosterol biosynthesis inhibitors. For example, inhibition of ergosterol 
biosynthesis can severely compromise mitochondrial function (181). However, the 
consequences of azole treatment upon the function and integrity of intracellular 
membranes and organelles are not well characterized. 
 
 A recent high-throughput screen conducted in our laboratory identified several 
imidazole antifungals as disrupting vacuolar integrity in C. albicans. Previous studies 
have indicated that ergosterol is required for endocytic trafficking from the plasma 
membrane to the fungal vacuole (95), and to support homotypic vacuole-vacuole fusion 
 
 
-------------------- 
* Modified by permission of American Society for Microbiology. Luna-Tapia A, Kerns 
ME, Eberle KE, Jursic BS, Palmer GE. 2015. Trafficking through the late endosome 
significantly impacts Candida albicans tolerance of the azole antifungals. Antimicrob 
Agents Chemother 59:2410–2420. doi:10.1128/AAC.04239-14.  
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in an in vitro biochemical assay. In addition, ergosterol biosynthetic (erg) mutants of 
Saccharomyces cerevisiae exhibit defects in vacuolar fusion and are known to have 
aberrant vacuole morphologies (96, 97). Furthermore, it has recently been proposed that 
ergosterol depletion following azole treatment impairs the function of the V-ATPase (79) 
responsible for vacuolar acidification, which in turn is required for many processes in this 
organelle. This is of significance as defects in vacuolar function and acidification 
substantially diminish C. albicans capacity to endure physiological stress, produce tissue 
invasive hyphae, and cause lethal infections in mice (49, 51, 166, 182-184). Furthermore, 
severe defects in vacuolar biogenesis can severely impair C. albicans growth rates (49). 
However, it remains unknown whether azole-induced vacuolar disruption contributes to 
the overall antifungal activity of the azoles, and in turn, how defective vacuolar function 
may influence susceptibility to the azoles. Thus, the objective of this chapter is to 
characterize the effects of azole treatment upon the integrity of the C. albicans vacuole. 
 
 
Materials and Methods 
 
 
Growth and media conditions 
 
 All C. albicans strains were routinely grown on yeast extract-peptone-dextrose 
(YPD) agar plates or in liquid medium at 30°C and supplemented with uridine (50 
μg/mL) when necessary. Transformant selection was carried out on minimal YNB 
medium (6.75 g/L yeast nitrogen base without amino acids, 2% dextrose, 2% Bacto agar), 
supplemented with the appropriate auxotrophic requirements as described for S. 
cerevisiae (185) or uridine at 50 μg/mL. All C. albicans strains were stored frozen at -
80°C in 20% glycerol. 
 
 For growth curves, overnight cultures in YPD at 30○C were sub-cultured into 15 
mL fresh YNB medium at an initial cell concentration of 1 x 106 cells/mL in the presence 
of 1 μg/mL fluconazole or 0.5% dimethyl sulfoxide (DMSO - drug free control), and 
incubated at 30°C with shaking. Samples were taken every 30 minutes and optical 
density was determined spectroscopically at 600 nm. 
 
 
Plasmid construction 
 
 All oligonucleotides used in this study are listed in Table 2-1. Plasmid 
pKE1:GFP-YPT72 (186) for expression of the GFP-Ypt72 fusion protein to label the 
vacuolar membrane was made by amplifying the coding sequence of the previously 
described GFP-YPT72 gene fusion (51) with primer set GFPSALIF + YPT72ORFR-
MluI, and cloning the product downstream of the ACT1 promoter, between the SalI and 
MluI sites of the pKE1 expression vector (187). Plasmid pKE1:CPP-GFP was constructed 
as follows. The coding sequence of the predicted C. albicans Cpy1p prepropetide (codons 
1-129) (188), was amplified by PCR from SC5314 gDNA using the primers CPPORFF- 
SalI and CPPORFR-EagI, and cloned between the SalI and EagI restriction  
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Table 2-1. List of oligonucleotides used in the study described in Chapter 2. 
 
Primer Sequence (5’-3’) 
ARG4DETF ATCAATTAACACAGAGATACC 
ARG4DETR CCGAGCTTGGCGTAATCATGG 
ARG4INTF2  AAGCTAGTGTGGAAAGAAGAG 
ARG4INTR2  AATGACTGAATTATGTCGGTC 
CPPORFF-SalI TCAGTCGACATGAAGTTATCAAAATCCAC 
CPPORFR-EagI TCAGGGCCGACCACCACCACCTTTAATTC 
ERG11AMPF2-KpnI TCAGGTACCAATGAAAATGTCGTGGGGAGC 
ERG11DISF 
TTCTTTCCATATTACTTGTCTTCTTTTTATTATATATATAAG
TTTCTTTTCAAGAAGATCATAACTCAATGTTTTCCCAGTC
ACGACGTT 
ERG11DISR 
TGTGTTAATCCAACTAAGTAACAAAATGAAAACAATCTG
AACACTGAATCGAAAGAAAGTTGCCGTTTTATGTGGAAT
TGTGAGCGGATA 
ERG11F-KpnI-SalI TCAGGTACCGTCGACGCCAACAGAATTACTACCCAA 
ERG11ORFF TCAGTCGACATGGCTATTGTTGAAACTGTC 
ERG11ORFR TCAACGCGTTGAATCGAAAGAAAGTTGCCG 
ERG11R-KpnI-MluI TCAGGTACCACGCGTTTGGGTAGTAATTCTGTTGGC 
ERG11SEQR1 TTTTCATAACATTGGCAACCC 
ERG11TETOF  
AAATCAATTTTTATATATAAATAGACAAAGAAAGGGAAT
TCAATCGTTATTCTTTCCATATTACTTGTCGTAATACGACT
CACTATAGGG 
ERG11TETOR 
ATCTGTTGTGTAACACTAAGGGACAAAAAATAATTAATG
CCATCAATGACAGTTTCAACAATAGCCATCTAGTTTTCT
GAGATAAAGCTG 
ERG3AMPF-SacI TCAGAGCTCGACTACGCGAGACCACACTTGC 
ERG3AMPR-SacI TCAGAGCTCGTGAAATTACTTACAATATGGAG 
ERG3DETF  GCTGATGTTTTCCCTAAAGATGG 
ERG3DETR GTAAGAGTTACCAAGTCTATCCC 
ERG3DISF 
CCCTTCCCATTTCTTTCCCTATTGTGCATATAAGTTCAATC
TTTTTTTCTTTCTTTCGGATTCGGTTTAGTGTGGAATTGT
GAGCGGATA 
ERG3DISR 
GGAAAAATAGTCAATGGTCCAAAACAAAGATGTACCAA
TCATTGTTCAACATATTCTCTATCGTCAACTTGTTTTCCC
AGTCACGACGTT 
GFPAMP-MluI TCAACGCGTTTATTTGTACAATTCATCC 
GFPEAGF TCACGGCCGATGTCTAAAGGTGAAGAATTATTC 
GFPSALIF  TCAGTCGACATGTCTAAAGGTGAAGAATTATTC 
HIS1DETF TCATCCTCCAGGATCCCGCGG 
HIS1DETR TGTCACCTAAATAGCTTGGCG 
HIS1INTF2 ACTGTATCCTCTTCTGTCCCC 
HIS1INTR2 CGACCATATGGGAGAGCTCCC 
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Table 2-1. (Continued). 
 
Primer Sequence (5’-3’) 
LUXINTDETF CTGACCTTTAGTCTTTCCTGC 
LUXINTDETR CAGTAGTACTTGTTGTTGTATCG 
TETODETF GTTGACACTTCTAAATAAGCG 
URA3DISF1 ATGACAGTCAACACTAAGACC 
URA3DISF2  
CCACTAAGGAATTCCTTGAATCAAGAAGAAGGATTTGAT
TGGCT 
URA3DISR2 CAAATAAGCATTCCAACCAGC 
URA3DISR3-SacII TCACCGCGGCAATATGAGTCTTGATTAAGC 
URA3INTF TTAGTGTTACGAATCAATGGC 
URA3INTF2 TTATACCATCCAAATCCCGCG 
URA3INTR CAATTATAAATGTGAAGGGGG 
YPT72ORFR-MluI TCAACGCGTTTTGTTCTCTTTCTTCACCTG 
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sites of pKE1 (187). A C. albicans codon-optimized GFP coding sequence was then 
amplified by PCR from plasmid pGFPURA3 (189) using primers GFPEAGF and 
GFPAMPR-MluI, and cloned in-frame and downstream of the CPY1 prepropeptide 
coding sequence, between EagI and MluI sites to yield the CPP-GFP fusion construct. 
 
 Plasmid pGUD1 was constructed as follows. A 210 bp portion of the 3’ end of the 
URA3 ORF was amplified from pGEM-URA3 (190) with primer set URA3DISF2 + 
URA3DISR2, and cloned into the vector pGEM®-T Easy (Promega). A 193 bp portion 
of the 5’ end of the URA3 ORF was then amplified using the primer set URA3DISF1 and 
URA3DISR3-SacII. This product was then digested with SphI and SacII and cloned 
between the same sites of the pGEM®-T Easy vector, adjacent to the 3’ end of the URA3 
gene. This produced an ura3 allele lacking a 390 bp central portion of the ORF. 
 
 
C. albicans strain construction 
 
 Strains used in this study are listed in Table 2-2. Gene deletion strains were 
constructed by the PCR-based approach described by Wilson et al., (190), using the 
ura3∆/∆his1∆/∆arg4∆/∆ strain BWP17 (kindly provided by Dr. Aaron Mitchell, 
Carnegie Mellon University). 
 
 ERG3 deletion cassettes were amplified by PCR with primer pair ERG3DISF + 
ERG3DISR, using pRS-ARG4∆SpeI or pGEM-HIS1 (190) as templates. Each ERG3 
allele was sequentially deleted from strain BWP17 using ARG4 and HIS1 markers to 
generate erg3∆/∆ura3∆/∆ gene deletion mutants. Correct integration of deletion cassettes 
was confirmed at each step by PCR with the following primer sets: ARG4INTF2 + 
ERG3AMPR-SacI and ARG4INTR2 + ERG3AMPF-SacI (ARG4 integration), or 
HIS1INTF2 + ERG3AMPR-SacI and HIS1INTR2 + ERG3AMPF-SacI (HIS1 
integration). The lack of an intact ERG3 allele was confirmed using primer pair 
ERG3DETF and ERG3DETR. 
 
 Strain THE1 (191) was kindly provided by H. Nakayama and M. Arisawa 
(Nippon Roche). One allele of ERG11 was deleted using the recyclable URA3-dpl200 
selection marker, which was amplified from pDDB57 with primer pair ERG11DISF + 
ERG11DISR. Correct integration was then confirmed by PCR using primer pair 
URA3INTR + ERG11R-KpnI-MluI. The resulting strain was then made ura3- through 5-
fluoroorotic acid (5’FOA) selection on YNB medium supplemented with uridine and 1 
μg/mL 5’FOA (192) in order to isolate ura3- segregants that had excised the URA3 
marker gene. Excision of the URA3 gene was confirmed using the flanking primer set 
ERG11AMPF2 + ERG11R-KpnI-MluI (1307 bp product) (186). 
 
 The native 5’ UTR of the second ERG11 allele was then replaced with a URA3-
tetO promoter cassette which was amplified from plasmid p97CAU (191), using 
ERG11TETOF + ERG11TETOR primers. Correct promoter replacement was confirmed 
using primer pair TETODETF + ERG11SEQR1 to confirm integration of the tetO 
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Table 2-2. List of strains used in the study described in Chapter 2. 
 
 
Strain Relevant Genotype Reference 
CAI4 ura3∆/∆ (193) 
BWP17 ura3∆/∆ his1∆/∆ arg4∆/∆ (190) 
THE1 ura3∆/∆ ade2∆/∆ ENO1/∆:ENO1-tetR-ScHAP4AD-3× HA-ADE2 (191) 
CAI4 + GFP-YPT72 ura3∆/∆:URA3:GFP-YPT72 This study 
CAI4 + CPP-GFP ura3∆/∆:URA3:CPP-GFP This study 
erg3∆/∆+ GFP-YPT72 ura3∆/∆:URA3:GFP-YPT72 his1∆/∆ arg4∆/∆ erg3∆:HIS1/erg3∆:ARG4 This study 
erg11∆/ERG11 + GFP-YPT72 ura3∆/∆:URA3:GFP-YPT72 ade2∆/∆ ENO1/∆:ENO1-tetR-ScHAP4AD-3× 
HA-ADE2 erg11∆:dpl200/ERG11 
This study 
erg11∆/tetO-ERG11 + GFP-YPT72 ura3∆/∆:URA3:GFP-YPT72 ade2∆/∆ ENO1/∆:ENO1:tetR-ScHAP4AD-3× 
HA-ADE2 erg11∆:dpl200/tetO-ERG11 
This study 
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promoter upstream of the remaining ERG11 ORF, and ERG11AMPF2-KpnI + 
ERG11SEQR1 to confirm the absence of a native ERG11 allele (186). 
 
 Next the erg11∆/tetO-ERG11 strain was transformed with a URA3 deletion 
cassette that was amplified from plasmid pGUD1 with primer pair URA3DISF1 + 
URA3DISR2. This consisted of the URA3 ORF lacking a 390 bp internal sequence. 
Transformants were then selected on 5’FOA plates (see above), and correct disruption of 
the URA3 ORF confirmed using primer pair URA3DISF1 + URA3DISR2 that flank the 
internal deletion sequence of URA3. The absence of an intact URA3 ORF (792 bp), and 
presence of a truncated product (402 bp) confirmed that the URA3 selection marker had 
been successfully disrupted (186). 
 
 Plasmid pKE1:GFP-YPT72 linearized with NheI was introduced into the ura3- C. 
albicans strain CAI4 (193), erg3Δ/Δura3Δ/Δ and erg11∆/tetO-ERG11ura3Δ/Δ, and 
transformants selected on YNB medium lacking uridine. For construction of the CPP-
GFP expressing strain of C. albicans, the pKE1:CPP-GFP expression plasmid was 
linearized with NheI, transformed into strain CAI4, and URA3+ transformants selected. 
Correct integration of either expression construct fully restores the URA3 and adjacent 
IRO1 loci, and this was confirmed by PCR analysis using primer pair LUXINTDETF + 
LUXINTDETR which yields a 2199 bp product following restoration of the ura3 locus. 
 
 
Fluorescence microscopy to determine vacuole morphology construction 
 
 Vacuole morphology of C. albicans strains was determined using a GFP-Ypt72p 
or CPP-GFP fusion protein expressed from pKE1. Cells were observed with an Olympus 
BX51 fluorescence microscope with a 100X objective and a fluorescein isothiocyanate 
(FITC) filter set to detect GFP fluorescence. For each field matching phase contrast and 
FITC fluorescence images were acquired using a QImaging MicroPublisher 3 RTV 
camera (QImaging) and the CellSens® Digital Imaging Software (Olympus). 
Adjustments in the brightness and/or contrast of images were made using the CellSens® 
Digital Imaging software. All images presented for a given time point/condition of each 
experiment were scaled identically to permit direct comparison. In some instances, 
imaging was performed using a Cytation 5™ Cell Imaging Multi-Mode Reader (BioTek). 
 
 
Results 
 
 
Azole antifungals cause severe vacuolar disruption in C. albicans 
 
 During a high-throughput screen, we recently identified a variety of imidazole 
antifungals, including miconazole and ketoconazole, as causing disruption of C. albicans 
vacuolar integrity (unpublished results). This was further confirmed by fluorescence 
microscopy using a strain expressing the GFP-tagged GTPase Ypt72p which localizes to 
the surface of C. albicans vacuole (51). As shown in Figure 2-1A, treatment with   
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Figure 2-1. Azole antifungals cause severe disruption of the C. albicans vacuole. 
A C. albicans strain expressing GFP-Ypt72p was treated with (A) 1.5 μg/mL of 
miconazole (MCZ), (B) 1 μg/mL of fluconazole (FLU) or 0.5% DMSO in YNB and 
grown at 30°C for 4 and 6 hours, respectively. Imaging of vacuolar integrity was 
performed by fluorescence microscopy using a FITC filter set to detect GFP 
fluorescence. PC: phase contrast. 
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miconazole caused severe disruption of vacuolar integrity, further confirming the results 
obtained in the chemical screen. 
 
 Several imidazoles have been proposed to possess secondary antifungal 
mechanisms that account for their fungicidal activity at high concentrations, which are 
independent of their inhibition of ergosterol biosynthesis (85, 86, 194, 195); however, 
these mechanisms have not been described for the triazoles. We therefore tested if the 
fungistatic triazole fluconazole, caused similar perturbation of the C. albicans vacuole. 
Using the C. albicans strain expressing GFP-Ypt72p fusion protein, we determined that 
treatment with fluconazole caused similar disruption of vacuolar integrity as did 
miconazole (Figure 2-1B). A similar observation was made when the vacuoles were pre-
labeled with the lipophilic dye FM4-64, which is endocytosed and accumulates within the 
vacuolar membrane (Figure 2-2). This indicates that both imidazole and triazoles share a 
common mechanism leading to C. albicans vacuole disruption, presumably Erg11p 
inhibition. 
 
 
Vacuole disruption caused by fluconazole treatment occurs before growth inhibition 
is observed 
 
 In order to determine the sequence of events leading to vacuole disruption 
following azole treatment, we performed a time-course experiment. The C. albicans 
GFP-Ypt72p tagged strain was sub-cultured into YNB medium ± 1 μg/mL fluconazole, 
and growth, cell viability as well as vacuolar morphology compared at 30 minute 
intervals. When growth was measured as OD600nm, statistically significant growth 
inhibition was initially observed in the presence of fluconazole at the 420 minutes time 
point (Figure 2-3A). However, when cell viability was compared in the same cultures as 
colony forming units (CFU), fluconazole was found to significantly reduce CFU’s vs. the 
drug free control at the 330 minute time point (Figure 2-3C). In the presence of 
fluconazole, significant vacuolar fragmentation was initially observed at the 240 minute 
time point and is pronounced by 270 minutes (Figure. 2-3B). This precedes the reduction 
in CFU and the effect on OD600nm, suggesting that vacuolar degeneration is an early event 
following azole treatment and not merely a secondary consequence of a prolonged 
growth arrest. Similar observations were also made using a C. albicans strain expressing 
a GFP tagged version of Carboxypeptidase Y (Figure 2-4), which labels the vacuolar 
lumen. 
 
 
Disruption of vacuolar integrity occurs upon inhibition of Erg11p 
 
 In order to confirm that the observed vacuolar defects were a direct consequence 
of Erg11p inhibition, rather than an ‘off-target’ effect of the azoles, we constructed a 
strain in which the transcription of the ERG11 gene could be shut-down using a 
doxycycline repressible promoter. In the presence of doxycycline, the tetO-ERG11 strain 
showed similar degeneration of GFP-Ypt72p labeled compartments to those observed 
following fluconazole treatment (Figure 2-3D). This confirmed that the vacuolar defects  
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Figure 2-2. The integrity of the C. albicans vacuole is severely compromised after 
azole treatment. 
The vacuole of a C. albicans strain expressing the GFP-Ypt72p fusion protein was 
labeled with FM4-64 in YPD medium for 30 minutes. Cells were then sub-cultured into 
fresh YNB medium ± 4 μg/mL of fluconazole (FLU) at 1 x 106 cells/mL and grown at 
30°C for 4 hours. Imaging of vacuolar integrity was performed by fluorescence 
microscopy using a FITC filter set to detect GFP fluorescence or TRITC for FM4-64 
detection. 
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Figure 2-3. Inhibition of Erg11p causes vacuolar fragmentation in C. albicans. 
(A, B and C) A C. albicans strain expressing the GFP-Ypt72p fusion protein was sub-
cultured into YNB broth supplemented with either 1 μg/mL fluconazole or 0.5% DMSO 
(minus drug control) at ~1 x 106 cells/mL and incubated at 30°C with shaking. Samples 
were taken at 30 minutes intervals and growth measured as OD600nm (A) and cell viability 
as colony forming units (CFU). Vacuolar integrity was also observed by fluorescence 
microscopy using a FITC filter set (C) and matching phase contrast (PC) images also 
obtained. Data in panels (A) and (B) are the mean and standard deviation of two 
independent experiments, and the images in panel (C) are representative of each time 
point in the same two experiments. Growth and CFU’s were compared ± fluconazole for 
each time point using a two tailed t-test. * P < 0.05; § P < 0.001. (D) The C. albicans 
ERG11 gene was placed under the transcriptional control of a doxycycline repressible 
promoter and the GFP-Ypt72p expression construct introduced into the tetO-ERG11 
strain. The tetO-ERG11 strain was then sub-cultured into YNB medium ± 5 μg/mL of 
doxycycline (Dox) at 1 x 105 cells/mL and incubated at 30°C with shaking. After 8 hours 
vacuole morphology was observed as described above. 
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Figure 2-4. Azole treatment severely disrupts the integrity of C. albicans vacuole. 
A fusion protein consisting of the first 129 amino acids of Carboxypeptidase Y (Cpy1p) 
fused to GFP was expressed in C. albicans under the ACT1 promoter, in order to 
fluorescently label the vacuolar lumen. YNB broth ± 1 μg/mL of fluconazole (FLU) was 
inoculated at 1 x 106 cells/mL. Samples were taken hourly and vacuolar integrity was 
observed by fluorescence microscopy using a FITC filter set. 
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induced by azole treatment are a direct consequence of Erg11p inhibition, and thus 
presumably result from depletion of cellular ergosterol. 
 
 
Erg3p modulates the severity of vacuole disruption in azole treated C. albicans 
 
 Ergosterol depletion together with accumulation of the toxic sterol 14α-
methylergosta-8,24(28)-dien-3β,6α-diol in the plasma membrane following azole 
treatment are thought to result in loss of its integrity and ultimately growth arrest (141). 
The production of 14α-methylergosta-8,24(28)-dien-3β,6α-diol depends upon Erg3p (C-5 
sterol desaturase) activity since loss of Erg3p function results in the accumulation of its 
precursor 14α-methylfecosterol in the plasma membrane, which allows continued growth 
following azole treatment (81, 141). Whether production of toxic sterols mediated by 
Erg3p upon azole exposure contributes to loss of integrity of intracellular membranes 
such as the fungal vacuole is unknown. 
 
 In order to test whether Erg3p function impacts vacuole integrity after azole 
exposure, we constructed an erg3Δ/Δ mutant expressing the fusion protein GFP-Ypt72p 
and determined its vacuole morphology by fluorescence microscopy. As shown in Figure 
2-5, the erg3Δ/Δ mutant exhibited a rather normal vacuole morphology in the absence of 
fluconazole. While treatment with 2 μg/mL of fluconazole caused severe loss of vacuole 
integrity in the WT control strain as previously shown, the severity of vacuole disruption 
in the erg3Δ/Δ mutant was reduced under similar conditions (Figure 2-5). This suggests 
that an active Erg3p, and thus presumably the toxic sterols that it synthesizes following 
azole treatment, exacerbates the severity of vacuole disruption. 
 
 
Discussion 
 
 Azoles inhibition of fungal growth is often assumed to be a consequence of 
plasma membrane dysfunction caused by both depletion of cellular ergosterol, and the 
accumulation of ‘toxic’ sterol intermediates (196). Here, we established that inhibition of 
lanosterol demethylase (Erg11p) with azoles or through transcriptional repression led to 
significant perturbation of vacuolar integrity in the fungal pathogen C. albicans. 
Moreover, vacuolar degeneration was an early consequence of azole treatment. We have 
previously demonstrated that C. albicans mutants with severe defects in vacuolar 
biogenesis, have impaired growth, stress tolerance, polarized hyphal growth and 
pathogenicity (49-51, 166). Thus it is possible that vacuolar dysfunction may make a 
significant contribution to the overall antifungal activity of the azoles. Previous studies 
have also noted that several non-essential Saccharomyces cerevisiae ergosterol 
biosynthetic mutants have a fragmented vacuole morphology, and ergosterol is required 
for homotypic vacuole-vacuole fusion (170, 171). We have shown that mutants of C. 
albicans lacking Erg2p or Erg24p, the targets of the morpholine antifungals, have distinct 
degrees of degeneration of vacuolar integrity (172), which is worsened when both targets 
are pharmacologically repressed with ergosterol biosynthesis inhibitors such as 
amorolfine and fenpropimorph. Like the C. albicans erg2Δ/Δ and erg24Δ/Δ mutants, the  
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Figure 2-5. Loss of Erg3p reduces the impact of azole treatment upon vacuolar 
integrity in C. albicans. 
C. albicans WT (CAI4) and erg3Δ/Δ mutant strains expressing the GFP-Ypt72p fusion 
protein were treated with 2 μg/mL of fluconazole or 0.5% DMSO for 6 hours in YNB 
medium. Vacuole morphology was determined with a CytationTM 5 Cell Imaging Multi-
Mode Reader using a GFP filter cube. PC: phase contrast. 
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erg3Δ/Δ mutant is expected to have no ergosterol. However, the erg3Δ/Δ mutant has a 
lesser degree of vacuolar degeneration than the former mutants. In addition, the C. 
albicans erg3Δ/Δ mutant has a lesser degree of deterioration of vacuolar integrity when 
treated with azole antifungals than a WT strain. This indicates that the degree of vacuolar 
degeneration does not depend only on the absence of ergosterol, but rather depends on 
the specific steps blocked along the ergosterol biosynthetic pathway. This may be 
explained by differences in the physical or chemical properties of the specific sterol 
intermediates that accumulate following blockage of a particular step. Different sterol 
species have been shown biochemically to confer different structural properties upon 
membranes (197), and thus the accumulation of a particular sterol may alter the structure 
of a cellular membrane. 
 
 Recent studies by Rao and colleagues have also suggested that ergosterol is 
required for the activity of the V-ATPase responsible for vacuolar acidification, which in 
turn is required for normal vacuolar membrane fusion (198, 199). However, it is likely 
that ergosterol depletion in itself affects the structural integrity of the vacuole, and 
potentially the activity of a multitude of other vacuolar membrane proteins. Thus the 
precise interdependence between ergosterol availability, V-ATPase activity, vacuolar 
integrity and the antifungal efficacy of the azoles, remains to be elucidated. 
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CHAPTER 3.    VACUOLAR TRAFFICKING THROUGH THE LATE 
ENDOSOME/PREVACUOLAR COMPARTMENT SIGNIFICANTLY 
IMPACTS AZOLE SUSCEPTIBILITY OF CANDIDA ALBICANS* 
 
 
Introduction 
 
 Recent evidence points to a significant role of ergosterol in the function of the 
fungal vacuole. For example, ergosterol is required for endocytosis (169) and homotypic 
vacuole fusion (170, 171), and has been suggested to be required for the activity of the V-
ATPase responsible for vacuolar acidification (79). In Chapter 2 we showed that Erg11p 
inhibition following exposure to azole antifungals drastically impacts the integrity of the 
C. albicans vacuole and this is dependent upon Erg11p inhibition. Moreover, we 
determined that severe fragmentation of the vacuole can be observed as an early event 
following azole treatment, occurring before significant growth inhibition is observed. 
Thus it is likely that the vacuolar defects observed upon azole treatment contribute to the 
antifungal activity of the azoles, as vacuolar dysfunction renders C. albicans more 
susceptible to a wide variety of stresses, can impair growth and hyphae development, and 
reduces its pathogenic capacity in vivo (49, 51, 166). Nevertheless, whether vacuolar 
dysfunction can impact the antifungal activity of the azoles is unknown. 
 
 Normal membrane trafficking to the fungal vacuole is required for C. albicans to 
respond to a multitude of stressors, hyphal growth, biofilm formation and its ability to 
cause disease. Many mutants with impaired vacuolar membrane trafficking are deficient 
in one or more of the aforesaid biological processes (50, 51, 187, 200). Several 
membrane trafficking pathways that deliver material to the vacuole have been 
characterized in the non-pathogenic model yeast S. cerevisiae (Figure 3-1), all of which 
make significant contributions to normal vacuolar function (201). The alkaline 
phosphatase (ALP) trafficking pathway delivers its cargo directly from the Golgi to the 
vacuole (Figure 3-1). Membrane trafficking through the ALP pathway requires the AP3 
adaptor complex which consists of 4 proteins namely Apl6p, Apl5p, Apm3p and Aps3p 
(201). 
 
 The so called carboxypeptidase Y (CPY) trafficking pathway transports cargo 
from the Golgi to the vacuole, via an intermediate trafficking step at the late 
endosome/pre-vacuolar compartment (PVC, Figure 3-1). Targeting and fusion of Golgi-
derived vesicles with the PVC require the t-SNARE [Soluble N-ethylmaleimide-sensitive 
factor (NSF) attachment protein receptor] Pep12p/Vps6p in the target membrane (202), 
the v-SNARE protein Vti1p on the transport vesicle (203), the SM (Sec1/Munc18p-like)
 
 
-------------------- 
* Modified by permission of American Society for Microbiology. Luna-Tapia A, Kerns 
ME, Eberle KE, Jursic BS, Palmer GE. 2015. Trafficking through the late endosome 
significantly impacts Candida albicans tolerance of the azole antifungals. Antimicrob 
Agents Chemother 59:2410–2420. doi:10.1128/AAC.04239-14.  
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Figure 3-1. Membrane trafficking pathways to the vacuole of C. albicans analyzed 
in this study. 
The alkaline phosphatase pathway (ALP) delivers material from the Golgi apparatus to 
the vacuole and is dependent upon Aps3p. Both the carboxypeptidase Y (CPY) and the 
endocytic pathways carry material to the vacuole from the Golgi apparatus or the plasma 
membrane, respectively, via the late endosome/prevacuolar compartment; both are 
dependent upon Vps21p. The autophagocytic pathway transports material from the 
cytoplasm to the vacuole and is dependent upon Atg9p. Additionally, the role of Ypt72p 
(the C. albicans homolog of yeast’s Ypt7p) which controls membrane fusion events at the 
vacuole itself, was analyzed in this study. Mutants blocked in ALP trafficking (aps3Δ/Δ), 
endosomal trafficking (vps21Δ/Δ), autophagy (atg9Δ/Δ) or membrane fusion at the 
vacuolar membrane (ypt72Δ/Δ) were examined. 
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protein Vps41p, the small Rab GTPase Vps21p (204), the Rab exchange factor Vps9p 
(205), the Rab effector Vac1p/Vps19p/Pep7p (206), and membrane tethering factors of 
the class C Vps complex formed by Vps11p/Pep5p, Vps18p/Pep3p, Vps16p, and Vps33p 
(201). Once at the PVC, proteins destined for the vacuole are sorted, packed into 
membrane vesicles for transport to and fusion with the vacuolar membrane, or for 
retrograde transport back to the Golgi (201). 
 
 The endocytic trafficking pathway carries out the internalization of extracellular 
material and plasma membrane components for recycling or degradation in the fungal 
vacuole via endocytosis. Similar to the CPY pathway, the endocytic pathway converges 
at the PVC (201). At this stage, the fusion of vesicles arriving from the plasma membrane 
with the PVC requires the same components regulating membrane fusion of vesicles 
transported through the CPY trafficking pathway, including the Rab GTPase Vps21p 
(207). 
 
 During autophagy, bulk or selected material from the cytoplasm is sequestered 
into double-membrane compartments called autophagosomes that are delivered to the 
vacuole for degradation (Figure 3-1). Autophagy is induced in response to multiple 
stresses including nutrient starvation (208), or certain developmental events (209). 
Among the various proteins involved in autophagocytic trafficking, Atg9p is strictly 
required for autophagosome formation (210). 
 
 The last trafficking step of the ALP, CPY and autophagocytic pathways is 
characterized by fusion of transport vesicles with the vacuole (Figure 3-1), a process 
controlled by the Rab GTPase Ypt7p in yeast, together with other components that 
include the SNARE complex formed by Vam3p, Vti1p, Vps43p/Vam7p and Ykt6p, and 
the Class C complex (203, 211, 212). 
 
 The objective of the studies described in this chapter was to determine if vacuolar 
dysfunction, in the context of membrane trafficking to the vacuole, can impact azole 
susceptibility in C. albicans. 
 
 
Materials and Methods 
 
 
Growth and media conditions 
 
 C. albicans was routinely grown on yeast extract-peptone-dextrose (YPD) at 
30°C, supplemented with 50 μg/mL uridine when necessary. Transformant selection was 
carried out on minimal YNB medium (6.75 g/L yeast nitrogen base without amino acids, 
2% dextrose, 2% Bacto agar), supplemented with the appropriate auxotrophic 
requirements as described for S. cerevisiae (185) or 50 μg/mL uridine. 
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Plasmid construction 
 
 Plasmid pLUX (213), was kindly provided by Dr. William Fonzi (Georgetown 
University). Plasmids pLUXVPS21 and pKE1 have been previously described (51, 187). 
Plasmid pGUD1 was constructed as described in Chapter 2. All oligonucleotides used in 
this study are listed in Table 3-1. 
 
 
C. albicans strain construction 
 
 Strains used in this study are listed in Table 3-2. The vps21∆/∆, ypt72∆/∆, 
atg9∆/∆, aps3∆/∆, ypt52∆/∆, ypt53∆/∆, vps21∆/∆ypt52∆/∆, vps21∆/∆ypt53∆/∆, 
ypt52∆/∆ypt53∆/∆ and vps21∆/∆ypt52∆/∆ypt53∆/YPT53T27N mutants were constructed in 
previous studies (50, 51, 187, 214). The C. albicans pep12∆/∆ mutant and isogenic 
control strains (200), were kindly provided by Dr. Samuel A. Lee (University of New 
Mexico). The azole susceptible clinical isolate TW1 [isolate 1 from reference (125)] and 
the matched azole resistant isolate TW17 [isolate 17 from reference (125)] were kindly 
provided by Dr. Theodore C. White (University of Missouri-Kansas City). Control strain 
YJB6284 (215) was kindly provided by Dr. Judith Berman (University of Minnesota) and 
SC5314 has been previously described (216). 
 
 C. albicans was transformed with DNA constructs using the lithium acetate 
procedure (217). Gene deletion strains were constructed by the PCR-based approach 
described by Wilson et al., (190), using the ura3∆/∆his1∆/∆arg4∆/∆ strain BWP17 
(kindly provided by Dr. Aaron Mitchell, Carnegie Mellon University). The doxycycline 
repressible tetO-ERG11 strains were made using the system described by Nakayama and 
colleagues (191) as described in Chapter 2. 
 
 
Antifungal susceptibility testing 
 
 Antifungal susceptibility testing of all the strains included in this study was 
performed using the broth micro-dilution method described in the CLSI document M27-
A3 (218) in a 96-well plate format. All drugs for susceptibility testing used in this study 
were diluted in DMSO in 2-fold dilutions at 200 times the final concentration. 
Fluconazole (Sigma-Aldrich) concentrations tested ranged from 64 μg/mL to 0.0313 
μg/mL, Miconazole (Sigma-Aldrich) from 50 μg/mL to 0.024 μg/mL, Ketoconazole 
(Sigma-Aldrich) from 32 μg/mL to 0.015 μg/mL, Itraconazole (Sigma-Aldrich) from 16 
μg/mL to 0.007 μg/mL and Amphotericin B (LKT Laboratories, Inc.) from 16 μg/mL to 
0.001 μg/mL. RPMI 1640 medium (Sigma-Aldrich) was prepared according to the CLSI 
document. The medium was buffered with 0.165 M morpholinepropanesulfonic acid 
(MOPS) and pH adjusted using NaOH and HCl. Cell inoculum was ~ 1 x 103 cells per 
well. Plates were incubated without shaking at 35°C for 24 or 48 hours unless otherwise 
stated. The content of each well was carefully resuspended by pipetting up and down 
before OD600nm was measured using a Biotek Synergy Mx plate reader.  
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Table 3-1. List of oligonucleotides used in the study described in Chapter 3. 
 
Primer Sequence (5’-3’) 
ERG11AMPF2-KpnI TCAGGTACCAATGAAAATGTCGTGGGGAGC 
ERG11DISF 
TTCTTTCCATATTACTTGTCTTCTTTTTATTATATATATAAG
TTTCTTTTCAAGAAGATCATAACTCAATGTTTTCCCAGTC
ACGACGTT 
ERG11DISR 
TGTGTTAATCCAACTAAGTAACAAAATGAAAACAATCTG
AACACTGAATCGAAAGAAAGTTGCCGTTTTATGTGGAAT
TGTGAGCGGATA 
ERG11R-KpnI-MluI TCAGGTACCACGCGTTTGGGTAGTAATTCTGTTGGC 
ERG11SEQR1 TTTTCATAACATTGGCAACCC 
ERG11TETOF  
AAATCAATTTTTATATATAAATAGACAAAGAAAGGGAAT
TCAATCGTTATTCTTTCCATATTACTTGTCGTAATACGACT
CACTATAGGG 
ERG11TETOR 
ATCTGTTGTGTAACACTAAGGGACAAAAAATAATTAATG
CCATCAATGACAGTTTCAACAATAGCCATCTAGTTTTCT
GAGATAAAGCTG 
LUXINTDETF CTGACCTTTAGTCTTTCCTGC 
LUXINTDETR CAGTAGTACTTGTTGTTGTATCG 
TETODETF GTTGACACTTCTAAATAAGCG 
URA3DISF1 ATGACAGTCAACACTAAGACC 
URA3DISR2 CAAATAAGCATTCCAACCAGC 
URA3INTF2 TTATACCATCCAAATCCCGCG 
URA3INTR CAATTATAAATGTGAAGGGGG 
VPS21AMPR TCATCAGGATCCGTAAAATTGCACGACTGTGCC 
VPS21DETF GAGATATAACGATTGCATTGG 
VPS21DETF GCAACATGTGCTTCTTGGAGC 
VPS21DISF 
CCATCATTATTTCTACTATTTGTATTGCATTGTCGCATT
CAGGATCAAAGAGCCAAAATACATACTAGCATGTGGA
ATTGTGAGCGGATA 
VPS21DISR 
ACCATGGAGATCTGTACACACTTGCCTATTTGTATATTA
CCTTAACTTCAGTCTCCTTGTTTATTTATATTTTCCCAGT
CACGACGTT 
VPS21SEQF AATACTAGTAGTATCACCATC 
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Table 3-2. List of strains used in the study described in Chapter 3. 
 
  
Strain Relevant Genotype Reference 
SC5314 Wild-type/clinical isolate  
BWP17 ura3∆/∆ his1∆/∆ arg4∆/∆ (190) 
YJB6284 ura3∆/∆:URA3 his1∆/∆:HIS1 arg4∆/∆:ARG4 (215) 
THE1 ura3∆/∆ ade2∆/∆ ENO1/∆:ENO1-tetR-ScHAP4AD-3× HA-ADE2 (191) 
TW1 Matched azole susceptible clinical isolate (125) 
TW17 Matched azole resistant clinical isolate (125) 
vps21∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4 (51) 
vps21∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4  (51) 
ypt72∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ ypt72∆:HIS1/ypt72∆:ARG4 (51) 
ypt72∆/∆ + YPT72 ura3∆/∆:URA3:YPT72 his1∆/∆ arg4∆/∆ ypt72∆:HIS1/ypt72∆:ARG4  (51) 
atg9∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ atg9∆:HIS1/atg9∆:ARG4 (214) 
atg9∆/∆ + ATG9 ura3∆/∆:URA3:ATG9 his1∆/∆ arg4∆/∆ atg9∆:HIS1/atg9∆:ARG4 (214) 
aps3∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ aps3∆:HIS1/aps3∆:ARG4 (50) 
aps3∆/∆ + APS3 ura3∆/∆:URA3:APS3 his1∆/∆ arg4∆/∆ aps3∆:HIS1/aps3∆:ARG4 (50) 
ypt52∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ ypt52∆:HIS1/ypt52∆:ARG4 (187) 
ypt52∆/∆ + YPT52 ura3∆/∆:URA3:YPT52 his1∆/∆ arg4∆/∆ ypt52∆:HIS1/ypt52∆:ARG4 (187) 
ypt53∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ ypt52∆:HIS1/ypt52∆:ARG4 (187) 
ypt53∆/∆ + YPT53 ura3∆/∆:URA3:YPT53 his1∆/∆ arg4∆/∆ ypt53∆:HIS1/ypt53∆:ARG4 (187) 
ypt52∆/∆ypt53∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ ypt52∆:HIS1/ypt52∆:dpl200 
ypt53∆:ARG4/ypt53∆:dpl200 
(187) 
ypt52∆/∆ypt53∆/∆ + YPT52 ura3∆/∆:URA3:YPT52 his1∆/∆ arg4∆/∆ ypt52∆:HIS1/ypt52∆:dpl200 
ypt53∆:ARG4/ypt53∆:dpl200 
(187) 
ypt52∆/∆ypt53∆/∆ + YPT53 ura3∆/∆:URA3:YPT53 his1∆/∆ arg4∆/∆ ypt52∆:HIS1/ypt52∆:dpl200 
ypt53∆:ARG4/ypt53∆:dpl200  
(187) 
vps21∆/∆ypt52∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
ypt52∆:ARG4/ypt52∆:dpl200 
(187) 
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Table 3-2. (Continued). 
 
 
Strain Relevant Genotype Reference 
vps21∆/∆ypt52∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
ypt52∆:ARG4/ypt52∆:dpl200 
(187) 
vps21∆/∆ypt52∆/∆ + YPT52 ura3∆/∆:URA3:YPT52 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
ypt52∆:ARG4/ypt52∆:dpl200 
(187) 
vps21∆/∆ypt53∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
ypt53∆:ARG4/ypt53∆:dpl200 
(187) 
vps21∆/∆ypt53∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
ypt53∆:ARG4/ypt53∆:dpl200 
(187) 
vps21∆/∆ypt53∆/∆ + YPT53 ura3∆/∆:URA3:YPT53 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
ypt53∆:ARG4/ypt53∆:dpl200 
(187) 
vps21∆/∆ypt52∆/∆ypt53∆/YPT53T27N ura3∆/∆:URA3:YPT53T27N his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
ypt52∆:ARG4/ypt52∆:dpl200 ypt53∆:dpl200/YPT53 
(187) 
pep12∆/∆ ura3∆/∆arg4∆/∆ his1∆/∆:HIS1 pep12∆:dpl200/pep12∆:ARG4 (200) 
pep12∆/∆ + PEP12 ura3∆/∆ arg4∆/∆ his1∆/∆:HIS1:PEP12 pep12∆:dpl200/pep12∆:ARG4 (200) 
erg11∆/ERG11 ura3∆/∆:GFP-YPT72 ade2∆/∆ ENO1/∆:ENO1-tetR-ScHAP4AD-3× HA-
ADE2 erg11∆:dpl200/ERG11 
This study 
erg11∆/tetO-ERG11 ura3∆/∆:URA3 ade2∆/∆ ENO1/∆:ENO1:tetR-ScHAP4AD-3× HA-ADE2 
erg11∆:dpl200/tetO-ERG11 
This study 
erg11∆/tetO-ERG11vps21∆/∆ ura3∆/∆:URA3 ade2∆/∆ ENO1/∆:ENO1:tetR-ScHAP4AD-3× HA-ADE2 
erg11∆:dpl200/tetO-ERG11 vps21∆:dpl200/vps21∆:dpl200 
This study 
erg11∆/tetO-ERG11vps21∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 ade2∆/∆ ENO1/∆:ENO1:tetR-ScHAP4AD-3× HA-
ADE2 erg11∆:dpl200/tetO-ERG11 vps21∆:dpl200/vps21∆:dpl200 
This study 
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Quantification of cellular ergosterol 
 
 50 mL YNB broth plus either 4 μg/mL fluconazole or 0.5% DMSO was 
inoculated with 2 x 106 C. albicans cells/mL and grown at 35°C for 24 hours with 
shaking at 200 rpm. Total cellular sterols were then extracted using n-heptane as 
described by Arthington-Skaggs et al. (219). n-heptane from the organic phase was 
evaporated under reduced pressure (0.03 mm Hg) at -20oC. White powdery residue was 
dissolved in 0.5 mL CDCl3 (99.8% D contains 1% v/v TMS) and it was subject to proton 
NMR (Nuclear magnetic resonance) spectroscopy analysis. NMR was recorded on 
Varian 500 MHz INOVA instrument. The amounts of the ergosterol in these samples 
were estimated by comparison with the NMR integrals of methyl C-18 group at 0.562 
ppm to an internal TMS standard. The amount of ergosterol in these samples was 
calculated by standardizing these integrals with the C-18 methyl integral of a standard 
ergosterol sample (1 mg/mL; Sigma-Aldrich) that was prepared and the NMR was 
recorded by an identical procedure. 
 
 
Results 
 
 
Vps21p mediated trafficking through the pre-vacuolar compartment influences 
fungal growth in the presence of azoles 
 
 In the previous chapter we revealed that treatment with azole antifungals cause 
severe disruption of C. albicans vacuolar integrity. To gain further insight into the 
interaction between the antifungal activity of the azoles and vacuolar integrity, we tested 
the susceptibility of C. albicans mutants blocked in four distinct vacuolar trafficking 
steps (Figure 3-1), using the CLSI (Clinical and Laboratory Standards Institute) standard 
protocol for antifungal susceptibility testing (218). The susceptibility of mutants blocked 
in either autophagy (atg9∆/∆) (214), or in a direct Golgi-to-vacuole trafficking pathway 
(aps3∆/∆) (50), to miconazole (Figure 3-2A and 2B) and fluconazole (Figure 3-3A and 
3B) is not significantly different from their isogenic control strains. However, a vps21∆/∆ 
mutant, lacking a Rab GTPase that regulates membrane fusion and trafficking through 
the pre-vacuolar compartment (PVC), apparently has significantly reduced susceptibility 
to miconazole (Figure 3-2C), fluconazole (Figure 3-3C), itraconazole (Figure 3-4A) 
and ketoconazole (Figure 3-4B) as judged by the enhanced growth of the mutant versus 
the control strains in the presence of any of these azole antifungals. Interestingly, a 
ypt72∆/∆ mutant lacking a Rab GTPase (the homolog of Ypt7p of S. cerevisiae) that 
localizes to the vacuole itself also showed slightly elevated growth in the presence of 
both fluconazole and miconazole (Figure 3-3D and Figure 3-2D, respectively), but the 
difference was less dramatic than for the vps21Δ/Δ mutant. This suggests that trafficking 
through the PVC is more important with respect to determining azole sensitivity, than 
trafficking to the vacuole per se. The susceptibility of the vps21∆/∆ mutant to 
Amphotericin B, which acts by directly binding ergosterol, is not significantly different 
from the isogenic control strain (Figure 3-4C). Furthermore, the vps21∆/∆ mutant has an 
increased susceptibility to the allylamine antifungal terbinafine (Figure 3-5A), which   
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Figure 3-2. Endosomal trafficking influences the growth of C. albicans in the 
presence of miconazole. 
The susceptibility of several C. albicans vacuolar trafficking mutants to miconazole was 
compared to ‘wild-type’ (YJB6284) and ‘reconstituted’ control strains using the standard 
CLSI broth microdilution protocol. After 48 hours incubation, growth was measured as 
OD600nm and expressed as a percentage of the growth in the minus drug (DMSO alone) 
control wells. (A) An atg9∆/∆ mutant blocked in autophagy. (B) An aps3∆/∆ mutant 
blocked in a direct Golgi-to-vacuole trafficking pathway. (C) A vps21∆/∆ mutant blocked 
in membrane fusion and trafficking through the PVC. (D) An ypt72∆/∆ mutant blocked in 
membrane fusion at the vacuolar membrane. The mean and standard deviation of two 
independent experiments are presented in each panel. 
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Figure 3-3. Endosomal trafficking defects alter C. albicans growth in the presence 
of fluconazole. 
The susceptibility of several C. albicans vacuolar trafficking mutants to fluconazole was 
compared to ‘wild-type’ (YJB6284) and ‘reconstituted’ control strains using the standard 
CLSI broth microdilution protocol. After 48 hours incubation, growth was measured as 
OD600nm and expressed as a percentage of the growth in the minus drug (DMSO alone) 
control wells. (A) An atg9∆/∆ mutant blocked in autophagy. (B) An aps3∆/∆ mutant 
blocked in a direct Golgi-to-vacuole trafficking pathway. (C) A vps21∆/∆ mutant blocked 
in membrane fusion and trafficking through the PVC. (D) A ypt72∆/∆ mutant blocked in 
membrane fusion at the vacuolar membrane. The mean and standard deviation of three 
independent experiments are presented in each panel. The growth of each mutant was 
compared to that of the ‘wild-type’ control at each drug concentration using a two-tailed 
t-test. * P < 0.05. 
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Figure 3-4. The Rab GTPase Vps21p impacts C. albicans growth in the presence 
of the triazole itraconazole and the imidazole ketoconazole. 
The C. albicans vps21Δ/Δ mutant and isogenic control strains were tested for their 
susceptibility to (A) itraconazole, (B) ketoconazole, and (C) the polyene amphotericin B 
using the standard CLSI broth microdilution protocol. After 48 hours incubation, growth 
was measured as OD600nm and expressed as a percentage of the growth in the minus drug 
(DMSO alone) control wells. The mean and standard deviation of two independent 
experiments are presented in each panel. 
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Figure 3-5. Endosomal trafficking impacts C. albicans susceptibility to other 
ergosterol biosynthesis inhibitors. 
The susceptibility of the C. albicans vps21Δ/Δ mutant to the allylamine terbinafine (A) 
and the morpholine amorolfine (B) was also determined as described above, except that 
growth was measured after 24 hours incubation. The mean and standard deviation of 
three independent experiments are presented in each panel. The growth of each mutant 
was compared to that of the ‘wild-type’ control at each drug concentration using a two-
tailed t-test. * P < 0.05. 
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inhibits an earlier step of the ergosterol biosynthetic pathway, and to amorolfine (Figure 
3-5B), which acts downstream of Erg11p. Thus the vps21∆/∆ mutants’ phenotype seems 
to be specific to the azoles, rather than a general ‘drug resistance’ phenotype. 
 
 
The VPS21 paralogs YPT52 and YPT53 do not significantly affect azole 
susceptibility 
 
 We recently described two additional GTPases that localize to the PVC, are 
closely related to, and share significant functional overlap with Vps21p (187). However, 
the ypt52∆/∆ and ypt53∆/∆ mutants lacking these GTPases are unaffected in their 
susceptibility to miconazole (Appendix A, Figure A-1A and B), as is a 
ypt52∆/∆ypt53∆/∆ double mutant (Appendix A, Figure A-1C). While the ypt52∆/∆ 
single mutant has slightly elevated growth in the presence of fluconazole compared to the 
isogenic control strain (Figure 3-6A), the ypt53∆/∆ mutant is unaffected (Figure 3-6B). 
Furthermore, vps21∆/∆ypt52∆/∆ (Appendix A, Figure A-1E), vps21∆/∆ypt53∆/∆ 
(Appendix A, Figure A-1F), and a triple GTPase mutant (Figure 3-6C), were all 
affected by fluconazole to a similar extent as the vps21∆/∆ single mutant. Thus despite 
significant functional overlap between these three Rab GTPases, it seems that the Vps21p 
GTPase has the greatest effect upon C. albicans growth in the presence of the azoles 
under standard MIC testing conditions. 
 
 
Susceptibility to azole antifungals is determined by the trafficking step controlled by 
Vps21p rather than a Vps21p specific function 
 
 To further determine if the growth phenotype shown by the C. albicans vps21Δ/Δ 
mutant in the presence of the azoles represents a specific function of the Vps21p GTPase, 
or is a feature of the trafficking step controlled by Vps21p, we tested the azole 
susceptibility of a C. albicans pep12∆/∆ mutant (200). Pep12p is a t-SNARE protein that 
is a downstream effector of Vps21p, and also facilitates membrane fusion events at the 
PVC (202). The growth of the pep12∆/∆ mutant (Figure 3-7) shows a similar dose-
response to fluconazole as that described above for the vps21∆/∆ mutant (Figure 3-3C), 
suggesting that this phenotype is a result of a block in PVC transport rather than a 
specific function of the Vps21p GTPase. 
 
 Interestingly, a C. albicans vps28∆/∆ mutant lacking a subunit of the ESCRT I 
protein sorting complex that controls biogenesis of multivesicular bodies (MVB, which 
form by invagination of the limiting endosomal membrane for internalization of 
membrane proteins that are to be sorted to the vacuole) (220) was no more sensitive or 
tolerant to fluconazole treatment than the control strains (Appendix A, Figure A-2). This 
underscores the importance of the trafficking step mediated by Vps21p in determining 
azole susceptibility in C. albicans over other membrane trafficking events within the 
PVC.  
 49 
 
Figure 3-6. The Vps21p paralogs Ypt52p and Ypt53p have minimal effect upon C. 
albicans growth in the presence of fluconazole. 
C. albicans ypt52∆/∆ (A), ypt53∆/∆ (B), vps21∆/∆ypt52∆/∆ypt53∆/YPT53:YPT53
T27N
 
(triple GTPase mutant) (C) mutants and their isogenic control strains were tested for their 
susceptibility to fluconazole using the standard CLSI broth microdilution protocol. After 
48 hours incubation, growth was measured as OD600nm and expressed as a percentage of 
the growth in the minus drug (DMSO alone) control wells. The data in each panel is the 
mean and standard deviation of three independent experiments. The growth of each 
mutant was compared to that of the ‘wild-type’ control at each drug concentration using a 
two-tailed t-test. * P < 0.05. 
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Figure 3-7. The C. albicans pep12∆/∆ mutant has reduced susceptibility to 
fluconazole. 
C. albicans pep12∆/∆ mutants and their isogenic control strains were tested for their 
susceptibility to fluconazole using the standard CLSI broth microdilution protocol. After 48 
hours incubation, growth was measured as OD600nm and expressed as a percentage of the 
growth in the minus drug (DMSO alone) control wells. The mean and standard deviation of 
three independent experiments is shown. The growth of the pep12∆/∆ mutant was compared to 
that of the ‘wild-type’ control at each drug concentration using a two-tailed t-test. * P < 0.05. 
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The C. albicans vps21∆/∆ mutant exhibits an exaggerated ‘trailing growth’ 
phenotype 
 
 The dose-response profiles of the vps21∆/∆ mutant to fluconazole are distinct 
from that of a well characterized azole resistant isolate TW17 (125) (Figure 3-8A and B). 
When growth was compared at the earlier time point of 24 hours, it could be discerned 
that the growth of the vps21∆/∆ mutant was inhibited at similar concentrations of 
fluconazole to the isogenic control strain, but the degree of growth inhibition was 
significantly less (Figure 3-9A). In addition, above concentrations of 0.5 µg/mL no 
further ‘dose-dependent’ decrease in growth was observed. The differential dose-
response profiles at 24 vs. 48 hours (Figure 3-9A and B) are characteristic of the ‘trailing 
growth’ phenomenon (124). Clinical isolates exhibiting ‘trailing growth’ typically exhibit 
MIC’s of ≤ 1 µg/mL at the 24 hour time point, but ≥ 64 µg/mL at 48 hours. Using a strict 
cutoff of 80% growth inhibition (MIC80) the vps21∆/∆ mutant would be considered azole 
resistant at both 24 and 48 hour time points. However, adopting a less stringent criterion 
of 50% growth inhibition (MIC50), the vps21∆/∆ mutants’ differential response at 24 vs. 
48 hours conforms to that of ‘trailing growth’. While trailing isolates are generally 
considered to be susceptible to azole treatment in vivo (143, 144), the phenomenon can 
complicate in vitro antifungal susceptibility testing since it can lead to misclassification 
of susceptible isolates as resistant ones, impacting therapeutic decisions. Furthermore, the 
mechanisms underlying trailing growth are not well understood. We therefore examined 
if the increased growth of the vps21∆/∆ mutant in the presence of the azoles was true 
resistance, or an exaggerated ‘trailing growth’ phenotype. It has been previously reported 
that adjusting the pH of the RPMI growth medium from 7 to a more acidic pH is 
sufficient to eliminate trailing growth, but not true azole resistance (124). At pH 3, the 
vps21∆/∆ mutant still grew more than the isogenic control strain in the presence of 
fluconazole (Figure 3-9C), but the differential was substantially diminished. It has also 
been reported that adjusting the incubation temperature from 35°C to 25°C or 42°C 
eliminates trailing growth (221). The vps21Δ/Δ mutant was completely re-sensitized to 
fluconazole at either 25 or 42°C (Figure 3-9D and E), further supporting that the 
vps21Δ/Δ mutants reduced growth inhibition in the presence of the azoles is an 
exaggerated form of the trailing growth phenomenon, rather than outright resistance. 
 
 
The vps21∆/∆ mutant is tolerant of Erg11p inhibition and ergosterol depletion 
compared to control strains 
 
 The dose-response data for the 24 hour time point suggest that the potency of the 
azoles with respect to Erg11p inhibition is unchanged in the vps21∆/∆ mutant, but that 
the in vitro antifungal efficacy (i.e. impact on growth), is reduced under standard testing 
conditions. We therefore considered the possibility that the vps21∆/∆ mutant has a 
decreased dependence upon ergosterol for growth, or that it was more tolerant than wild-
type of the toxic sterol intermediates that accumulate upon azole treatment. To test this 
we compared cellular ergosterol levels in the vps21∆/∆ and isogenic control strain, in the 
presence and absence of fluconazole. This confirmed that both vps21∆/∆ and control 
strains are similarly depleted of ergosterol following treatment with fluconazole   
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Figure 3-8. The dose-response growth profile of the vps21∆/∆ mutant to 
fluconazole is distinct from that of an azole resistant clinical isolate. 
A well described, azole susceptible isolate (TW1) and an azole resistant matched strain 
(TW17), the vps21∆/∆ mutant, reconstituted control strain (vps21∆/∆ + VPS21), and 
additional “wild-type” control strains (SC5314 and YJB6284) were tested for their 
susceptibility to fluconazole using the standard CLSI broth microdilution protocol. 
Growth was determined as OD600nm after 24 hours (A) and 48 hours (B) incubation and 
expressed as a percentage of the growth in the minus drug (DMSO) control wells. The 
means and standard deviations of two biological replicates is shown. 
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Figure 3-9. The C. albicans vps21Δ/Δ mutant shows features consistent with an 
exaggerated trailing growth-like phenotype. 
The susceptibility of the vps21∆/∆ mutant and control strains to fluconazole was tested 
using the standard CLSI protocol and growth compared at either 24 hours (A) or 48 hours 
(B). The same experiment was also conducted with RPMI medium that was adjusted to a 
pH of 3 (C); or at pH 7 with incubation at either 25 (D) or 42°C (E) and growth compared 
after 48 hours of incubation. Data in panels A-E are the mean and standard deviation of 
three independent experiments. The growth of the vps21∆/∆ mutant was compared to the 
WT control at each concentration of fluconazole using a two-tailed t-test; * P < 0.05. (F) 
The vps21Δ/Δ mutant and isogenic control strains were cultured in YNB broth ± 4 µg/mL 
of fluconazole at 35°C for 24 hours, before total cellular sterols were extracted and 
ergosterol content quantified by NMR analysis. Ergosterol content is expressed as a 
percentage of the samples wet weight. A C. albicans erg2Δ/Δ mutant (no fluconazole) 
was used as negative control for ergosterol. (G) Both VPS21 alleles were deleted from the 
tetO-ERG11 strain. The growth of the resulting vps21∆/∆, ‘reconstituted’ and ‘wild-type’ 
(YJB6284) control strains was then compared using a broth microdilution assay in YNB 
medium supplemented with a range of doxycycline concentrations. Growth was 
measured as OD600nm and expressed as a percentage of growth occurring in the minus 
doxycycline control wells. The mean and standard deviation of three independent 
experiments is indicated, and statistical analysis was performed as described above. 
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(Figure 3-9F). Furthermore, NMR analysis of cellular n-heptane extracts from mutant 
and control cells indicates that there are no significant differences in the composition of 
the sterol intermediates that accumulate upon fluconazole treatment (Appendix A, 
Figure A-3A and B). Thus the elevated growth of the vps21∆/∆ mutant is unlikely to be 
accounted for by altered azole uptake, efflux or target inhibition. 
 
 The above results suggest that despite fluconazole inhibiting Erg11p (and 
ergosterol biosynthesis) to similar extents, the vps21∆/∆ mutant is able to grow more than 
its isogenic control, at least under standard MIC testing conditions. To provide further 
support for this argument, we deleted both VPS21 alleles from the tetO-ERG11 strain 
described above. This enabled us to repress Erg11p activity at a transcriptional level and 
independently of the azole drugs. Doxycycline suppressed the growth of the isogenic 
control strain, but growth was suppressed to a much lesser extent in the vps21∆/∆ 
background (Figure 3-9G). Together, these data suggest that the elevated growth of the 
vps21∆/∆ mutant in the presence of the azoles relates more to a mitigation of the 
consequences of Erg11p inhibition and ergosterol depletion, rather than a reduction in 
Erg11p inhibition. 
 
 
Discussion 
 
 An important finding of this study is that vacuolar trafficking pathways through 
the PVC are an important determinant of antifungal tolerance. Blocking the PVC 
trafficking steps controlled by the Rab GTPase Vps21p and t-SNARE Pep12p does not 
seem to affect the azoles capacity to inhibit ergosterol biosynthesis (i.e. potency), but 
significantly reduces the resulting impact upon fungal growth under standard 
susceptibility testing conditions (35°C, pH 7). The differential dose-response curves at 24 
vs. 48 hours, as well as the pH and temperature dependence of the vps21∆/∆ mutants’ 
decreased susceptibility to the azole antifungals are consistent with it being an 
exaggerated form of the ‘trailing growth’ phenotype that has been described for about 
18% of C. albicans isolates (145). The mechanism(s) that underlie trailing growth are not 
well understood, and whether altered endosomal trafficking is a contributing factor to the 
trailing growth observed in clinical isolates remains to be established. Tests on a limited 
number of clinical isolates have suggested that the trailing growth phenotype is usually 
associated with in vivo susceptibility to azole therapy (143, 144). Thus we would expect 
the vps21∆/∆ and pep12∆/∆ mutants to be susceptible in vivo. Similarly, it will be 
important to determine if altered endosomal trafficking contributes to the differences in in 
vitro as well as in vivo antifungal efficacy that are observed between clinical isolates. 
 
 Others have reported that a C. albicans vps15Δ/Δ mutant, defective in retrograde 
trafficking from the PVC back to the Golgi is highly sensitive to fluconazole (222). 
Furthermore, two mutants lacking components of the ESCRT complex that facilitates the 
formation of intra-lumenal multi-vesicular bodies from the PVC’s surface membrane are 
also sensitive to fluconazole (223). A further finding of potential clinical relevance is that 
the vps21∆/∆ mutant is significantly more susceptible to terbinafine and amorolfine, 
antifungal medications that target alternate steps within the ergosterol biosynthetic 
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pathway. This suggests that membrane trafficking through the PVC compartment is an 
important determinant of susceptibility to the antifungal agents that target ergosterol 
biosynthesis. Furthermore, chemical agents that interfere with specific endosomal 
trafficking steps may sensitize pathogenic fungi, and enhance the antifungal efficacy of 
therapies that target the ergosterol biosynthetic pathway. 
 
 Several major components of sterol biosynthesis are localized to the endoplasmic 
reticulum (173). While the mechanisms responsible for sterol redistribution to other 
cellular membranes are poorly understood (224), they are believed to involve both 
vesicular transport and non-vesicular carrier-protein mediated processes (224-226). Thus 
one explanation may be that membrane trafficking defects at the PVC could lead to the 
sub-cellular redistribution of the sterol intermediates that accumulate upon treatment with 
ergosterol biosynthesis inhibitors. The methylated sterols that accumulate upon azole 
treatment are thought to contribute to cellular membrane dysfunction and growth 
inhibition (196). Thus the redistribution of these potentially toxic sterols to distinct 
compartments within the fungal cell could determine the specific cellular organelles 
affected, and thus the cellular consequences of antifungal treatment. For example, 
blocking Vps21p mediated membrane trafficking through the PVC may divert the 
transport of the ‘toxic’ sterol intermediates produced within the endoplasmic reticulum 
upon azole treatment, away from a cellular compartment that is especially sensitive, and 
redistribute them to a cellular compartment that can better tolerate them. Conversely, the 
same mechanism renders the vps21∆/∆ mutant more sensitive to the sterol intermediates 
species that accumulate following treatment with terbinafine or amorolfine. Viewed in 
this light, the impact of antifungal treatment upon the fungal cell is determined not only 
by ergosterol depletion, but a combination of the chemical and physical properties of the 
specific sterol intermediate that accumulates (i.e. which steps of ergosterol are blocked), 
as well as the cellular destination to which they are transported. 
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CHAPTER 4.    AZOLE TOLERANCE IN CANDIDA ALBICANS MUTANTS 
LACKING THE RAB GTPASE VPS21P IS DEPENDENT UPON CALCIUM 
SIGNALING*† 
 
 
Introduction 
 
 A form of azole tolerance known as “trailing growth” denotes the persistent 
growth of some clinical isolates of C. albicans and other Candida species, at drug 
concentrations higher than the minimum inhibitory concentration (MIC). A “trailing” 
isolate exhibits azole susceptibility at the 24 hour time-point but appears similar to an 
azole resistant isolate after 48 hours incubation under standard susceptibility testing 
conditions (144), despite substantial reduction in cellular ergosterol levels (143, 219). 
However, experiments carried out in animal models of mucosal and disseminated 
candidiasis indicate that strains displaying trailing growth in vitro are susceptible to 
azoles in vivo (143, 144). 
 
 The mechanisms underlying trailing growth as well as the biological significance 
of this phenomenon remain unclear. Some studies have suggested that upregulation of 
genes related to several azole resistance mechanisms such as ERG11, CDR1, CDR2 and 
MDR1 in response to azole treatment may play a role in the trailing growth phenomenon 
(227). However, no direct correlation has been established between ERG11, CDR1 and 
MDR1 expression levels, or particular amino acid substitutions in Erg11p with the 
trailing phenomenon (123). 
 
 In Chapter 3 we showed that endosomal trafficking is a key determinant of the 
consequences of ergosterol biosynthesis inhibition, as a C. albicans vps21Δ/Δ mutant 
deficient in membrane fusion events at the PVC is tolerant of the azole antifungals, but 
more sensitive to exposure to the allylamine terbinafine and morpholine amorolfine. 
Remarkably, the vps21Δ/Δ mutant was able to grow significantly more than the control 
strains in the presence of the azole antifungals despite ergosterol depletion, a phenotype 
that resembled an exaggerated form of the trailing growth phenomenon that has been 
described for some clinical isolates. However, the mechanisms by which the vps21Δ/Δ 
mutant exerts this phenotype are unknown. The objective of the studies described in this
 
 
-------------------- 
* Modified by permission of American Society for Microbiology. Luna-Tapia A, Kerns 
ME, Eberle KE, Jursic BS, Palmer GE. 2015. Trafficking through the late endosome 
significantly impacts Candida albicans tolerance of the azole antifungals. Antimicrob 
Agents Chemother 59:2410–2420. doi:10.1128/AAC.04239-14. 
 
† Modified by permission of American Society for Microbiology. Luna-Tapia A, Tournu 
H, Peters TL, Palmer GE. 2016. Endosomal trafficking defects can induce calcium 
dependent azole tolerance in Candida albicans. Antimicrob Agents Chemother 60:000 –
000. doi:10.1128/AAC.01034-16.   
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chapter is to define the mechanisms underlying the azole tolerance of the vps21Δ/Δ 
mutant. 
 
 
Materials and Methods 
 
 
Growth conditions 
 
 C. albicans was routinely grown in YPD medium (1% yeast extract, 2% peptone, 
2% dextrose) at 30°C, supplemented with uridine (50 μg/mL) when necessary. 
Transformant selection was carried out on minimal YNB medium (6.75 g/L yeast 
nitrogen base without amino acids, 2% dextrose, 2% Bacto agar), supplemented with the 
appropriate auxotrophic requirements as described for S. cerevisiae (185) or 50 μg/mL 
uridine. 
 
 
Plasmid construction 
 
 Plasmid pLUX (213), was kindly provided by Dr. William Fonzi (Georgetown 
University). Plasmids pLUXVPS21 (51), pKE1 (187), and pKE1-NLUC (172) were 
previously described. All oligonucleotides used in this study are listed in Table 4-1. 
 
 The VPH1 ORF with 5’ and 3’ UTR sequences was amplified from SC5314 
genomic DNA (gDNA) with HiFi Platinum Taq (Invitrogen) and primer set VPH1AMPF 
+ VPH1AMPR-KpnI, and cloned between the SacI and KpnI restriction sites of pLUX to 
produce plasmid pLUXVPH1. 
 
 pLUXCDR1 was produced by amplifying the CDR1 ORF with 5’ and 3’ 
untranslated region sequences from SC5314 genomic DNA (gDNA) with HiFi Platinum 
Taq (Invitrogen) and primer set CDR1AMPF2 + CDR1AMPR2, and then cloned 
between the NsiI and AgeI restriction sites of pLUX. 
 
 For construction of the reporter plasmid pRTA2prGFPγ (228), 1000 bp of the 
RTA2 promoter were amplified from SC5314 gDNA with HiFi Platinum Taq (Invitrogen) 
and primer pairs RTA2prF-KpnI + RTA2prR-SalI, and cloned between the KpnI and SalI 
sites of pKE1 in place of the ACT1 promoter. The GFPγ coding sequence was then 
amplified using GFPAMPF-SalI + GFPAMPR-MluI, and cloned downstream of the 
RTA2 promoter between SalI and MluI sites. 
 
 
C. albicans strain construction 
 
 Strains used in this study are listed in Table 4-2. Transformation of C. albicans 
with DNA constructs was performed using the lithium acetate method (217). Gene 
deletion strains were constructed by the PCR-based approach described by Wilson et al.   
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Table 4-1. List of oligonucleotides used in the study described in Chapter 4. 
 
  
Primer Sequence (5’-3’) 
ARG4DETF ATCAATTAACACAGAGATACC 
ARG4DETR CCGAGCTTGGCGTAATCATGG 
ARG4INTF2 AAGCTAGTGTGGAAAGAAGAG 
ARG4INTR2 AATGACTGAATTATGTCGGTC 
CDR1DISF 
ATATCACATATATATTCTATTTATTTTTTGTACTTAATAAT
TTCTTTAAAAGGTCAAAAACGAAAAAATTGTTTTCCCAGT
CACGACGTT 
CDR1DISR 
ATAGTCTAAAAACGTCTATTATATTTTAGACGTTTGAGAT
ACCACCATGTCAAAAAACAAACTGTTTAATTGTGGAATT
GTGAGCGGATA 
CDR1AMPF2 GTAGCAAGTGTGTCAAGAACC 
CDR1AMPR2 TCAACCGGTCAGATGAGAAACACTTTTTCCC 
CDR1DETF2 GGAGCTCAACGGAAAATTGCC 
CDR1DETF3 GGTGCCATGACTCCTGCTACCG 
CDR1DETR2 AGATGAGAAACACTTTTTCCC 
CDR1DETR3 CACCAGCGACACCAACTAGGGC 
GFPAMPF-SalI TCAGTCGACATGTCTAAAGGTGAAGAATTATTC  
GFPAMPR-MluI TCAACGCGTTTATTTGTACAATTCATCC 
HIS1DETF TCATCCTCCAGGATCCCGCGG 
HIS1DETR TGTCACCTAAATAGCTTGGCG 
HIS1INTR2 CGACCATATGGGAGAGCTCCC 
LUXINTDETF CTGACCTTTAGTCTTTCCTGC 
LUXINTDETR CAGTAGTACTTGTTGTTGTATCG 
MDR1DISF 
TTCCGTAACAATCATATTATAATTTTACATTGCCCCAATA
GCAATACATATACTTACATAGAACTTCATAGTTTTCCCAG
TCACGACGTT 
MDR1DISR 
CTTTTCTCTTTTTAATTATTGATTAATGTATCTATAACACG
ATATATCTATAGGAAAACAATGACACCTCTGTGGAATTGT
GAGCGGATA 
MDR1AMPF TCAGGATCCTCACACGAACAAAAACAACCC 
MDR1AMPR TCAGGATCCTAATGAGAACATTGTGTCCGCG 
MDR1DETF AATAGTTGTCACTTGGGATG 
MDR1DETR AGCACCCAAACTCCAAGCGGC 
RTA2prF-KpnI TCAGGTACCGAATGTTAACTAAGGGGTGG 
RTA2prR-SalI TCAGTCGACAGTTGAAGGGTGGGAATGAACTG 
URA3INTF TTAGTGTTACGAATCAATGGC 
URA3INTF2 TTATACCATCCAAATCCCGCG 
URA3INTF2 TTATACCATCCAAATCCCGCG 
URA3INTR CAATTATAAATGTGAAGGGGG 
URA3INTR2 CAAGAAGAAGGATTTGATTGGC 
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Table 4-1. (Continued). 
 
 
Primer Sequence (5’-3’) 
VPH1DISF 
CAACGACTAAAAGATAACCGTCATTCTCTTCACTAATATA
CTTCTGTTCCCCCCCCCTCTCTCTTATCCCTGTGGAATTGT
GAGCGGATA 
VPH1DISR 
GCTTTAATGAATGAATCTAAACAAGTTAAAAACCCCAAC
TCTATGGTTCTAGGCTTATAAAACACTGTCTGTTTTCCCA
GTCACGACGTT 
VPH1AMPF TCTGGAGCTCCGTATCTGCACC 
VPH1AMPR-KpnI TCAGGTACCCAATATTTATTGACATTGCTAGGG 
VPH1DETF CACAATTAGAAAGTGGTGGTGCC 
VPH1DETF2 CGGAAACAATGTCATCTATGG 
VPH1DETR CAACATATTTAATAATCCTGGTGG 
VPH1DETR2 GGATGAATAATCTCGATGAGC 
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Table 4-2. List of strains used in the study described in Chapter 4. 
 
 
Strain Relevant Genotype Reference 
SC5314 Wild-type/clinical isolate (229) 
CAI4 ura3∆/∆ (193) 
BWP17 ura3∆/∆ his1∆/∆ arg4∆/∆ (190) 
YJB6284 ura3∆/∆:URA3 his1∆/∆:HIS1 arg4∆/∆:ARG4 (215) 
vps21∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4 (51) 
vps21∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4  (51) 
cdr1∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ cdr1∆:HIS1/cdr1∆:ARG4 This study 
cdr1∆/∆ + CDR1 ura3∆/∆:URA3:CDR1 his1∆/∆ arg4∆/∆ cdr1∆:HIS1/cdr1∆:ARG4  This study 
vps21∆/∆cdr1∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
cdr1∆:ARG4/cdr1∆:dpl200 
This study 
vps21∆/∆cdr1∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
cdr1∆:ARG4/cdr1∆:dpl200 
This study 
vps21∆/∆cdr1∆/∆ + CDR1 ura3∆/∆:URA3:CDR1 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
cdr1∆:ARG4/cdr1∆:dpl200 
This study 
vph1∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vph1∆:HIS1/vph1∆:ARG4 This study 
vph1∆/∆ + VPH1 ura3∆/∆:URA3:VPH1 his1∆/∆ arg4∆/∆ vph1∆:HIS1/vph1∆:ARG4  This study 
vps21∆/∆vph1∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
vph1∆:ARG4/vph1∆:dpl200 
This study 
vps21∆/∆vph1∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
vph1∆:ARG4/vph1∆:dpl200 
This study 
vps21∆/∆vph1∆/∆ + VPH1 ura3∆/∆:URA3:VPH1 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
vph1∆:ARG4/vph1∆:dpl200 
This study 
CAI4 + ACT1prNLUC ura3∆/∆:URA3:ACT1prNLUC This study 
vps21∆/∆ + ACT1prNLUC ura3∆/∆:URA3:ACT1prNLUC his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4 This study 
CAI4 + RTA2prGFPγ ura3∆/∆:URA3:RTA2prGFPγ This study 
vps21∆/∆ + RTA2prGFPγ ura3∆/∆:URA3:RTA2prGFPγ his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4 This study 
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(190) using the ura3Δ/Δhis1Δ/Δarg4Δ/Δ strain BWP17 (kindly provided by Dr. Aaron 
Mitchell, Carnegie Mellon University). Strain CAI4 was kindly provided by Dr. William 
Fonzi (Georgetown University). 
 
 The vps21Δ/Δ, aps3Δ/Δ, and vps21Δ/Δaps3Δ/Δ mutants were constructed in 
previous studies (50, 51, 187, 214). Control strain YJB6284 (215) was kindly provided 
by Dr. Judith Berman (Tel Aviv University). 
 
 CDR1 deletion cassettes were amplified by PCR with HiFi Platinum Taq 
(Invitrogen) and primers CDR1DISF and CDR1DISR, using pRS-ARG4∆SpeI, pGEM-
HIS1, or pDDB57 (containing a recyclable URA3-dpl200 marker) (190, 230) as 
templates. Each CDR1 allele was sequentially deleted by using HIS1 and ARG4 markers 
to generate cdr1∆/∆ura3∆/∆ gene deletion mutants. Correct integration of deletion 
cassettes was confirmed at each step by PCR with the following primers sets: 
ARG4DETF + CDR1DETF2 and ARG4DETR + CDR1DETR2 (ARG4 integration), or 
HIS1DETF + CDR1DETF2 and HIS1DETR + CDR1DETR2 (HIS1 integration). The 
absence of an intact CDR1 allele was confirmed using primer pair CDR1DETF3 + 
CDR1DETR3. Finally, isogenic mutant and CDR1 reconstituted strains were produced by 
transforming the cdr1∆/∆ura3∆/∆ mutant with either pLUX (vector alone) or 
pLUXCDR1 following restriction digestion with NheI. Correct integration of the pLUX 
vector fully restores the URA3 and adjacent IRO1 loci, and this was confirmed by PCR 
analysis using primer pair LUXINTDETF + LUXINTDETR which yields a 2199 bp 
product following restoration of the URA3 and IRO1 loci. 
 
 A vps21∆/∆cdr1∆/∆ double mutant was also made from a 
vps21∆/∆ura3∆/∆arg4∆/∆ strain previously described (51). The first allele of CDR1 was 
deleted with the URA3-dpl200 selection marker and the second allele with the ARG4 
marker. Replacement of the first CDR1 allele with the URA3-dpl200 selection marker 
was confirmed using primer pairs URA3INTF + CDR1DETF2 and URA3INTR + 
CDR1DETR2. The resulting vps21∆/∆cdr1∆/∆ double mutant was then selected on YNB 
medium supplemented with uridine and 1 μg/mL 5-FOA (192) to select for ura3- 
segregants that had excised the URA3 marker gene. Correct excision of the URA3 marker 
from the cdr1∆:URA3-dpl200 loci was confirmed using the flanking primer pairs 
CDR1DETF2 and CDR1DETR2. Prototrophic and isogenic mutant and reconstituted 
control strains were then made by transforming the vps21∆/∆cdr1∆/∆ double mutant with 
NheI digested pLUX, pLUXVPS21 (51), and pLUXCDR1. Correct integration of the 
plasmids and reconstitution of the URA3 and IRO1 loci was confirmed as described 
above. 
 
 The MDR1 ORF was deleted using an identical strategy to that described above 
for CDR1, except the deletion cassettes were amplified with primers MDR1DISF and 
MDR1DISR. Correct integration of the MDR1 deletion cassettes was confirmed using 
primer pairs ARG4DETF + MDR1AMPF and ARG4DETR + MDR1AMPR (ARG4 
integration), HIS1DETF + MDR1AMPF and HIS1DETR + MDR1AMPR (HIS1 
integration), or URA3INTF + MDR1AMPF and URA3INTR + MDR1AMPR (URA3 
integration). Deletion of both MDR1 alleles was also confirmed by the absence of a PCR 
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product using primer pair MDR1DETF + MDR1DETR which binds to sequences within 
the deleted portion of MDR1. Prototrophic and isogenic mutant and reconstituted control 
strains were then made by transforming the mdr1∆/∆ mutant and vps21∆/∆mdr1∆/∆ 
double mutant with NheI digested pLUX. Correct plasmid integration and restoration of 
URA3 and IRO1 loci was determined as previously described. 
 
 VPH1 deletion cassettes were amplified by PCR with primers VPH1DISF + 
VPH1DISR, using pRS-ARG4∆SpeI, pGEM-HIS1, or pDDB57 (containing a recyclable 
URA3-dpl200 marker)(190, 230) as templates. Each VPH1 allele was sequentially deleted 
using HIS1 and ARG4 markers to generate vph1Δ/Δura3Δ/Δ gene deletion mutants (228). 
Correct integration of the deletion cassettes was confirmed at each step by PCR with the 
following primers sets: ARG4INTF2 + VPH1DETR2 and ARG4INTR2 + VPH1DETF2 
for ARG4 integration or HIS1INTR2 + VPH1DETF2 for HIS1 integration. The absence 
of an intact VPH1 allele was confirmed using primer pair VPH1DETF + VPH1DETR. 
Isogenic mutant and VPH1 reconstituted strains were produced by transforming the 
vph1Δ/Δura3Δ/Δ mutant with either pLUX (vector alone) or pLUXVPH1 after 
linearization with NheI. Correct plasmid integration and restoration of URA3 and IRO1 
loci was determined as described above. 
 
 Construction of a vps21Δ/Δvph1Δ/Δ double mutant from a 
vps21Δ/Δura3Δ/Δarg4Δ/Δ strain previously described (51) was carried out by deleting 
the first allele of VPH1 with the URA3-dpl200 selection marker and the second allele 
with the ARG4 marker (228). Replacement of the first VPH1 allele with the URA3-dpl200 
selection marker was confirmed using primer pairs URA3INTF2 + VPH1DETR2 and 
URA3INTR2 + VPH1DETF2. The resulting vps21Δ/Δvph1Δ/Δ double mutant was then 
selected on YNB-agar plates supplemented with uridine and 5-fluoroorotic acid (5-
FOA)(192) to select for ura3- segregants that had excised the URA3 marker gene. Correct 
excision of the URA3 marker from the vph1∆:URA3-dpl200 loci was confirmed using the 
flanking primer pair VPH1AMPF + VPH1AMPR-KpnI. Prototrophic and isogenic 
mutant and reconstituted control strains were then made by transforming the 
vps21Δ/Δvph1Δ/Δ double mutant with pLUX, pLUXVPS21, or pLUXVPH1 digested 
with NheI (228). Correct plasmid integration and restoration of URA3 and IRO1 loci was 
determined as previously described. 
 
 C. albicans strains expressing cytoplasmic Nano Luciferase® (Nluc) (231) 
(produced with permission from Promega Corporation), were produced using the 
previously described pKE1-NLUC plasmid (172), which was linearized using NheI, and 
transformed into ura3- recipient strains. Strains carrying the RTA2-GFPγ reporter were 
made by transforming CAI4 and vps21Δ/Δura3- strains with the NheI digested 
pRTA2prGFPγ. Correct plasmid integration and restoration of URA3 and IRO1 loci was 
determined as described above. 
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Luciferase based membrane integrity assay 
 
 C. albicans strains expressing a cytoplasmic version of Nano Luciferase (Nluc) 
(231) were cultured overnight in YPD at 30°C. 200 μl of each culture was then 
transferred to an Eppendorf tube and the cells pelleted using a microfuge. The culture 
supernatant was then removed, the cells resuspended in 1 mL YNB and further diluted 
1:100 in YNB medium. 200 μL of each cell suspension was then dispensed into the wells 
of a round bottomed 96-well plate. After 24 hour incubation in a 30°C or 35°C standing 
incubator, the cells in each well were resuspended by mixing using a multichannel 
pipette. The plates were then centrifuged at 1200 rpm in a benchtop centrifuge to pellet 
the cells. 50 μL of the culture supernatant was then transferred to a white flat-bottomed 
96 well plate and Nluc activity determined using the Nano-Glo® Luciferase Assay 
Reagent (Promega Corporation), as per the manufacturer’s instructions. Luminescence 
was then measured using a Cytation™ 5 plate reader (BioTek Instruments, Inc.). Growth 
in each well from the overnight incubation was also determined by measuring OD600nm 
from samples diluted 1:10 in distilled water using a separate flat bottomed 96-well plate, 
and each luminescence reading normalized to the corresponding OD600nm reading. 
 
 
Biomass measurement and determination of cell viability 
 
 C. albicans strains were grown overnight in YNB at 30°C, washed and 
subcultured into 50 mL of fresh YNB at 2 x 106 cells/mL, in the presence of 5 μg/mL of 
fluconazole or 0.5% DMSO and incubated at 30 or 35°C for 24 hours with shaking. Cell 
viability was then determined as colony forming units (CFU) from culture samples 
following appropriate dilution in YNB and plating to YPD agar plates. 40 mL of each 
culture was also pelleted at 3500 rpm, washed by resuspension in 5 mL of deionized 
H2O, and harvested by filtration using a preweighed 0.22 μm GS filter membrane 
(Millipore). Cell pellets were dehydrated at 65°C for 24 hours and dry weight determined 
(228). 
 
 
Antifungal susceptibility testing 
 
 Antifungal susceptibility testing of all the strains was performed using the broth 
micro-dilution method described in the CLSI document M27-A3 (218) in a 96-well plate 
format. All drugs for susceptibility testing used here were diluted in DMSO in 2-fold 
dilutions of 200 times the final concentration. RPMI 1640 medium (Sigma-Aldrich) was 
prepared according to the CLSI document (218), and the medium was buffered with 
morpholinepropanesulfonic acid (MOPS) and pH adjusted to 7.0 using NaOH. Plates 
were incubated without shaking at 35°C for 24 or 48 hours unless otherwise stated. The 
content of each well was carefully resuspended by pipetting up and down before OD600nm 
was measured using a Cytation™ 5 plate reader (BioTek Instruments, Inc.). 
Checkerboard assays with fluconazole (Sigma-Aldrich) and the calcineurin inhibitors 
CsA (Sigma-Aldrich) or FK506 (Tacrolimus, Tocris) were performed in a 96-well plate 
in MOPS-buffered RPMI 1640 pH 7.0 according to the CLSI standard. Susceptibility 
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testing using combinations of fluconazole (1 μg/mL) plus nisoldipine (0.39-50 μM) or 
ethylene glycol tetraacetic acid (EGTA, 50-500 μM) was performed as described above. 
Plates were incubated and growth measured as described before. 
 
 
Determination of intracellular free Ca2+ levels 
 
 The relative levels of intracellular free Ca2+ were determined by using the Ca2+ 
sensitive dye Fura 2-AM (EMD Millipore Corporation). C. albicans strains were grown 
overnight in YPD at 30˚C, washed in PBS, and approximately ~107 cells resuspended in 
200 μL PBS pH 7.2 (without CaCl2 and MgCl2) plus 10 µM Fura 2-AM. Each cell 
suspension was then dispensed into the wells of a round bottomed 96-well plate. 
Following incubation at 37˚C for 1 hour, cells were pelleted and washed three times with 
PBS. Fluorescence was determined by dual excitation at 340 nm and 380 nm with a 
single emission at 505 nm in a Cytation™ 5 plate reader (BioTek Instruments, Inc.) (228) 
with the relative Ca2+ levels expressed as the ratio of fluorescence intensities upon 
excitation at 380 nm and 340 nm (232). 
 
 
Quinacrine accumulation assay 
 
 Quinacrine is a weak base that accumulates in acidic membrane organelles such 
as the fungal vacuole in yeast (233) and is used as a qualitative measurement of organelle 
acidification. The unprotonated form of quinacrine enters the cell and becomes 
protonated upon entry into an acidic organelle, accompanied by a boost in its 
fluorescence intensity (234). Labeling of the C. albicans vacuole with quinacrine was 
performed as described by Baggett et al (233) with the following modifications. 10 mM 
quinacrine stocks were prepared in 1 M HEPES pH 7.6 and stored at -20°C until use. 
Cells were grown overnight in YPD medium at 30°C in a rotator. Approximately 5 x 107 
cells per sample of each strain were harvested by centrifugation at 8000 rpm for 30 
seconds and resuspended in 100 μL of assay buffer (100 mM HEPES plus 2% glucose). 
Quinacrine was added to one set of samples at a final concentration of 25 μM; an 
equivalent volume of 1 M HEPES pH 7.6 + 2% glucose was added to a second set of 
samples to determine cell autofluorescence. A minus cell control containing assay buffer 
and 25 μM quinacrine was included to determine quinacrine binding to plastic. Samples 
were incubated during 5 minutes at room temperature in the dark; then were pelleted at 
8000 rpm for 30 seconds and cells resuspended in 100 μL of fresh assay buffer without 
quinacrine and placed on ice until use. 100 μL of each sample were transferred to a black, 
flat bottom 96-well plate. Three samples per set per biological replicate were used. 100 
μL of assay buffer alone was added to three additional wells to determine medium 
background. Fluorescence intensity was determined in a Cytation™ 5 Cell Imaging 
Multi-Mode Reader (BioTek Instruments, Inc.). Excitation and emission were set at 490 
nm and 525 nm, respectively, with a 9 nm bandwidth. Net fluorescence intensity was 
normalized to the OD600nm of each sample and expressed as a fold change from the 
fluorescence intensity of the WT control strain (YJB6284). 
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GFPγ reporter assays 
 
 C. albicans strains expressing GFPγ (235) from the RTA2 promoter were grown 
overnight in YPD at 30˚C. Cells were then washed and resuspended in YNB and ~1.3 x 
106 cells per well were dispensed into a round bottomed 96-well plate. Cells were treated 
with either 1 µg/mL fluconazole or 0.5% DMSO, and incubated at 35˚C for 24 hours. 
GFPγ fluorescence intensity was then quantified using a Cytation™ 5 plate reader 
(BioTek Instruments, Inc.) with excitation at 488 nm and emission at 507 nm. Growth 
was determined by measuring OD600nm for normalization of the fluorescence signal. 
 
 
Results 
 
 
The C. albicans vps21Δ/Δ mutant is tolerant of azole induced membrane damage 
 
 We previously showed that the vps21Δ/Δ mutant exhibits enhanced growth in the 
presence of the azole antifungals versus WT controls, despite ergosterol depletion. We 
therefore examined plasma membrane integrity following azole mediated ergosterol 
depletion, to determine if the vps21Δ/Δ mutant exhibited signs of membrane damage. A 
cytoplasmic version of Nano Luciferase (Nluc – Promega Corp.) (231) was expressed in 
mutant and control strains, and Nluc release into the culture supernatant was determined 
following treatment with fluconazole for 24 hours. Interestingly, fluconazole treatment at 
35°C, caused significant Nluc release from the WT strain indicating loss of plasma 
membrane integrity (Figure 4-1A). However, at this temperature the vps21Δ/Δ mutant 
released significantly less Nluc upon fluconazole treatment than WT, indicating less 
membrane damage. In contrast, at 30°C the mutant released similar levels, or even 
slightly more Nluc than WT (Figure 4-1B), indicating that fluconazole induces similar 
levels of membrane permeabilization in either strain at the lower temperature. This is 
consistent with our previous observation that the continued growth of the vps21∆/∆ 
mutant in the presence of the azoles (as measured by OD600nm), occurs at 35°C but not 
30°C. 
 
 To further confirm the temperature dependence of the vps21∆/∆ mutant’s azole 
tolerance, we compared its growth in the presence and absence of fluconazole using two 
additional measures, dry weight and colony forming units (Figure 4-1C and D). By both 
measures, at 35°C the vps21∆/∆ mutant was more tolerant of fluconazole than WT, while 
at 30°C the growth of both strains was severely inhibited. As such, it appears that at 35°C 
the azole antifungals cause less membrane damage to the vps21∆/∆ mutant than WT, and 
this likely accounts for its continued growth. 
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Figure 4-1. The C. albicans vps21Δ/Δ mutant has delayed membrane damage 
following azole treatment. 
Nluc was expressed in the vps21Δ/Δ mutant and wild-type (CAI4) control strain, which 
were grown in 96-well plates with various concentrations of fluconazole. Culture 
supernatant was removed after 24 hours of incubation at (A) 35°C or (B) 30°C, Nluc 
activity assayed, and expressed as a percentage of the minus drug controls. The means of 
three biological replicates are shown for each drug concentration, and error bars indicate 
the standard deviation. The means of each group were compared using a two-tailed t-test, 
* P < 0.05. (C-D) The vps21Δ/Δ mutant and WT were grown in YNB at 2 x 106 cells/mL 
in the presence of 0.5% DMSO or 5 μg/mL of fluconazole (FLU) for 24 hours at 30°C or 
35°C. Biomass as measured by (C) dry weight and cell viability as measured by (D) 
CFUs were determined and expressed as a percentage of the DMSO control for each 
strain under each condition. The means ± standard deviations of two biological replicates 
are shown for all panels. The means of each group were compared using a two-tailed t-
test, * P < 0.05. 
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Azole tolerance in the C. albicans vps21Δ/Δ mutant does not depend upon Vph1p 
function 
 
 A recent study has proposed that inhibition of the V-ATPase proton pump may in 
part underlie the antifungal activity of the azoles (79). In yeast, delivery of the V-ATPase 
to the vacuolar membrane depends on trafficking through the PVC. A S. cerevisiae 
vps21Δ mutant is deficient in the delivery of the V-ATPase to vacuole, and thus its ability 
to acidify the vacuole is impaired, as evidenced by decreased accumulation of the weak 
base quinacrine within the fungal vacuole (236). We therefore determined whether 
vacuolar acidification was affected in our vps21∆/∆ mutant. Unexpectedly, our vps21Δ/Δ 
mutant accumulated more quinacrine than the isogenic control strains, indicating a more 
acidified vacuole (Figure 4-2A). In order to determine whether the altered vacuolar 
acidification within the vps21∆/∆ mutant contributed to its azole tolerance, we deleted 
both alleles of VPH1, a gene encoding for a vacuole-specific subunit of the V-ATPase 
(184). However, loss of VPH1 does not affect the susceptibility of the ‘wild-type’ control 
strain to fluconazole, or the trailing growth phenotype of the vps21Δ/Δ mutant (Figure 4-
2B). These data demonstrate that the azole tolerance of the vps21Δ/Δ mutant does not 
depend upon V-ATPase activity. 
 
 
Azole tolerance in the C. albicans vps21∆/∆ mutant is independent of the Cdr1p and 
Mdr1p efflux pumps 
 
 Many plasma membrane proteins are targeted for degradation within the vacuole 
following endocytic trafficking via the PVC. We have previously reported that the C. 
albicans vps21∆/∆ mutant has reduced rates of endocytosis (51). Thus we considered that 
reduced rates of uptake and degradation, may increase the ‘half-life’ of the well described 
Cdr1p and Mdr1p efflux pumps at the cell surface, and the resulting increase in 
abundance of these pumps may contribute to the tolerance of the vps21∆/∆ mutant. To 
test this we deleted both alleles of either CDR1 or MDR1 from the vps21Δ/Δ mutant and 
examined the azole susceptibility of the resulting vps21∆/∆cdr1∆/∆ and 
vps21∆/∆mdr1∆/∆ double mutants. Loss of MDR1 had no impact on the MIC of either 
the ‘wild-type’ control or the vps21∆/∆ mutant (not shown) as it is not typically 
expressed in susceptible strains (140). While loss of CDR1 caused a slight increase in 
azole susceptibility in the WT, it did not significantly affect the susceptibility of the 
vps21∆/∆ mutant (Figure 4-3). These results suggest that the azole tolerance of the 
vps21∆/∆ mutant does not depend upon the activity of either the Mdr1p or Cdr1p efflux 
pumps. 
 
 
The C. albicans vps21Δ/Δ mutant has elevated cytoplasmic calcium levels 
 
 Ca2+ based signaling has been shown to induce adaptive responses that promote 
C. albicans survival following azole treatment (147, 237). Moreover, intracellular Ca2+ is 
compartmentalized in different organelles, with the fungal vacuole being the major 
storage site (238). To determine if the vacuolar trafficking defects of the vps21Δ/Δ   
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Figure 4-2. Deletion of gene encoding for the V-ATPase subunit Vph1p from the 
vps21Δ/Δ mutant does not restore sensitivity to azole antifungals. 
(A) Quinacrine uptake in the vps21Δ/Δ mutant and control strains was measured from 
overnight cultures in YPD. The mean ± standard deviation of four biological replicates is 
shown. The means of each group were compared using a two-tailed t-test, *, P < 0.005; 
**, P < 0.006. (B) VPH1, encoding a vacuole specific subunit of the V-ATPase proton 
pump, was deleted from either wild-type or the C. albicans vps21Δ/Δ mutant, and the 
fluconazole susceptibility of each strain was compared to ‘wild-type’ (YJB6284), 
vps21Δ/Δ and ‘reconstituted’ control strains using the standard CLSI broth microdilution 
protocol each strain tested using the standard CLSI broth microdilution protocol. 
Following 48 hours incubation, growth was measured as OD600nm and expressed as a 
percentage of the growth in the minus drug (DMSO alone) control wells. The means ± 
standard deviations of two biological replicates are shown. No statistically significant 
differences were found between the growth of the vps21Δ/Δ and the vps21Δ/Δvph1Δ/Δ 
mutants. 
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Figure 4-3. Growth of the C. albicans vps21Δ/Δ mutant in the presence of 
fluconazole does not depend upon the Cdr1p efflux pump. 
Both alleles of the CDR1 gene were deleted from either ‘wild-type’ (YJB6284) or the 
vps21Δ/Δ mutant and the susceptibility of the resulting strains to fluconazole tested using 
the standard CLSI broth microdilution protocol. Following 48 hours incubation, growth 
was measured as OD600nm and expressed as a percentage of the growth in the minus drug 
(DMSO alone) control wells. The mean and standard deviation of three independent 
experiments is presented. No statistically significant differences were found between the 
growth of the vps21Δ/Δ and the vps21Δ/Δcdr1Δ/Δ mutants. 
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mutant impact cellular Ca2+ homeostasis, we measured levels of cytoplasmic calcium 
with the calcium-sensitive dye Fura 2-AM (232). As expected, the antiarrhythmic drug 
amiodarone (AMD), known to cause cytoplasmic Ca2+ surges in S. cerevisiae (239), 
increased intracellular free Ca2+ levels in our wild-type control strain (Figure 4-4A). The 
relative intracellular calcium levels for the vps21Δ/Δ mutant were higher than for the WT 
controls (Figure 4-4B) as indicated by higher 380nm/340nm fluorescence intensity 
ratios. This indicates that the C. albicans vps21Δ/Δ mutant has a calcium homeostasis 
defect. 
 
 
The C. albicans vps21Δ/Δ mutant’s azole tolerance is dependent on extracellular 
calcium 
 
 Azole tolerance in C. albicans and other fungi has been shown to be reliant on 
Ca2+ dependent signaling (147, 237), which in turn relies on the availability of both 
extracellular and intracellular free Ca2+ (152). We therefore examined the dependence of 
the vps21Δ/Δ mutant’s azole tolerance on extracellular Ca2+ levels. Addition of 1 mM 
CaCl2 to the medium did not significantly enhance the growth of both vps21Δ/Δ mutant 
and control strains in the presence of fluconazole (Figure 4-5A). However, the Ca2+ 
chelator EGTA reduced the mutant’s tolerance to fluconazole (Figure 4-5B and C), 
establishing a requirement for extracellular Ca2+ for its azole tolerance. Entry of 
extracellular Ca2+ into the fungal cells depends on several Ca2+ channels located at the 
plasma membrane including the voltage-gated calcium channel formed by Mid1p/Cch1p 
(161, 240), a high-affinity Ca2+ influx system. Treatment of the vps21Δ/Δ mutant with the 
voltage-gated Ca2+ channel blocker nisoldipine (Figure 4-5E) also reduced its azole 
tolerance, at concentrations far below that at which nisoldipine is toxic by itself (Figure 
4-5D). This further supports the conclusion that the vps21Δ/Δ mutant depends on 
extracellular Ca2+ in order to tolerate azole exposure. 
 
 In further experiments we evaluated the impact of the Ca2+ homeostasis defect of 
the vps21Δ/Δ mutant by characterizing the effect on azole tolerance of AMD, known to 
cause cytoplasmic Ca2+ surges due to an increase in Ca2+ fluxes from the media and 
intracellular stores (239) (Figure 4-5F and G). Surprisingly, under standard MIC testing 
conditions, AMD dramatically enhanced growth of the WT control strain in the presence 
of fluconazole (Figure 4-5G). In contrast, growth of the vps21Δ/Δ mutant in the presence 
of fluconazole was largely unresponsive to AMD (Figure 4-5G). This further confirms a 
Ca2+ homeostasis defect in the vps21Δ/Δ mutant and highlights the role of Ca2+ fluxes in 
azole tolerance in C. albicans in general. 
 
 
The C. albicans vps21Δ/Δ mutant’s azole tolerance is dependent upon calcineurin 
signaling 
 
 Signaling through the Ca2+-responsive phosphatase calcineurin has been shown to 
be required for azole tolerance in C. albicans (147), as pharmacologic or genetic   
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Figure 4-4. The C. albicans vps21Δ/Δ mutant has elevated intracellular levels of 
Ca2+. 
(A) The control strain SC5314 was treated with a range on concentrations of AMD for 2 
hours in order to induce Ca
2+
 fluxes into the cytoplasm, followed by staining with the 
Ca2+ sensitive dye Fura 2-AM. Fluorescent intensity with dual excitation and 340 nm and 
380 nm and single emission at 505 nm was measured in Cytation™ 5 multi-mode reader. 
Relative Ca
2+
 levels are expressed as the ratio of the fluorescence intensity at 380 nm and 
340 nm. The mean ± standard deviation of two experimental replicates from a 
representative experiment is shown. (B) Free intracellular levels of Ca2+ were measured 
in the vps21Δ/Δ mutant and control strains using Fura 2-AM. WT is strain YJB6284. 
Fluorescence was determined as described above. The relative intracellular levels of Ca2+ 
are expressed as the ratio of the fluorescence intensity upon excitation at 380 nm and 340 
nm. The means ± standard deviations of four biological replicates are shown. The means 
of each group were compared using a two-tailed t-test, * P < 0.0001. 
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Figure 4-5. The C. albicans vps21Δ/Δ mutant’s azole tolerance depends upon 
extracellular calcium. 
(A) The C. albicans vps21Δ/Δ mutants’ susceptibility to fluconazole was tested after 
addition of 1 mM of CaCl2
 
to the media, and compared to wild-type (YJB6284), and 
reconstituted control strains using the standard CLSI broth microdilution protocol. After 
48 hours incubation, growth was measured as OD600nm and expressed as a percentage of 
the growth in the minus drug (DMSO alone) control wells. (B and C) Growth of the C. 
albicans vps21Δ/Δ mutant and control strains was compared in the presence of various 
concentrations of the Ca
2+
 chelator EGTA without (B) or with 1 µg/mL of fluconazole 
(C). Growth was determined as above and is expressed as a percentage of the growth in 
the minus drug (DMSO) control wells. (D and E) The susceptibility of the vps21Δ/Δ 
mutant to the Ca
2+
 channel blocker nisoldipine (NIS) (D) and its effect on the mutant’s 
tolerance to fluconazole (E) was evaluated. Growth was determined and expressed as 
above. (F and G) The effect of the antiarrhythmic drug amiodarone (AMD) on the 
vps21Δ/Δ mutant’s azole tolerance was tested. Growth was determined and expressed as 
above. The means ± standard deviation of two biological replicates is shown in each 
panel. The means of each group were compared using a two-tailed t-test, * P < 0.05. 
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inhibition of this pathway renders the normally fungistatic azoles fungicidal (147, 150, 
241). Upon azole exposure, increased calcineurin activity enhances the transcription of a 
number of specific genes involved in plasma membrane maintenance and stress response, 
including RTA2 (148, 242). In order to evaluate the state of calcineurin signaling in the 
vps21Δ/Δ mutant, we compared the transcriptional activity of the calcineurin responsive 
gene RTA2 in mutant and control strains using a GFPγ based reporter construct. RTA2 is a 
stress related gene that encodes a phospholipid translocase whose expression depends on 
the calcineurin-dependent transcription factor Crz1p (151, 243, 244) and has been found 
to be upregulated in experimentally-induced azole resistant isolates (245). As expected, 
treatment with fluconazole enhanced GFPγ expression from the RTA2 promoter in the 
WT control strain (Figure 4-6A). Furthermore, treatment with the calcineurin inhibitor 
cyclosporine A suppressed fluconazole induced expression of GFPγ (Appendix B, 
Figure B-1), establishing the responsiveness of this reporter construct to calcineurin 
activity. Interestingly, treatment of the vps21Δ/Δ mutant with fluconazole induced a 
significantly larger response from the RTA2pr-GFPγ reporter than was observed for the 
WT control strain, indicating an enhanced calcineurin dependent response in the mutant 
after azole exposure (Figure 4-6A). 
 
 In order to further define the role of calcineurin activity in the vps21Δ/Δ mutant’s 
azole tolerance, we evaluated the impact of pharmacological inhibition of calcineurin 
signaling on the vps21Δ/Δ mutant and control strains after fluconazole exposure (Figure 
4-6B-D). Inhibition of calcineurin signaling with either cyclosporine A (Figure 4-6C) or 
tacrolimus (FK506) (Appendix B, Figure B-2A-C), eliminated the vps21Δ/Δ mutant’s 
azole tolerance. Collectively, these data indicate that the ability of the vps21Δ/Δ mutant 
to tolerate azole exposure is dependent upon calcineurin activity. 
 
 
Discussion 
 
 In previous chapters we established that the azole antifungals cause severe 
disruption of the C. albicans vacuole (Chapter 2) and that trafficking through the late 
endosome/PVC mediated by the Rab GTPase Vps21p is a determining factor of C. 
albicans response to azole exposure. Our vps21Δ/Δ mutant was able to tolerate azole 
treatment and grow despite ergosterol depletion (Chapter 3), but unexpectedly, the 
mutant was more sensitive to exposure to other ergosterol biosynthesis inhibitors than the 
control strains. The growth of the mutant in the presence of azole antifungals resembles 
the ‘trailing’ growth phenomenon that is observed for some clinical isolates when treated 
with triazoles and was independent of established mechanisms of azole resistance. Our 
results reveal that the C. albicans vps21Δ/Δ mutant releases less cytoplasmic content than 
WT strains following fluconazole treatment at 35°C, suggesting it sustains less 
membrane damage. In addition, we determined that the vps21Δ/Δ mutant has elevated 
levels of intracellular Ca2+ and that its growth in the presence of the azoles depends upon 
Ca2+ availability. This indicates that trafficking through the PVC mediated by Vps21p is 
not only important in maintaining Ca2+ homeostasis in C. albicans, but that the Ca2+ 
homeostasis defects that arise from defective endosomal trafficking have substantial  
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Figure 4-6. Inhibition of calcineurin signaling suppresses the vps21Δ/Δ mutant’s 
azole tolerance. 
(A) The RTA2pr-GFPγ expression construct was introduced into C. albicans strain CAI4 
(WT) and vps21Δ/Δ mutant, and the resulting strains were grown in YNB ± 1 µg/mL 
fluconazole for 24 hours. GFP fluorescence was quantified by excitation at 488 nm and 
emission at 507 nm, normalized for the cell density (OD600nm) of each strain and 
expressed as fold fluorescence of the DMSO control. The means ± standard deviations of 
four biological replicates are shown. The means of each group were compared using a 
two-tailed t-test: * P < 0.0004. (B-D) The growth of the vps21Δ/Δ mutant, WT 
(YJB6284) and reconstituted strain in the presence of both the calcineurin activity 
inhibitor cyclosporine A (CsA) and fluconazole was compared using a checkerboard 
assay. The growth of WT (B), vps21Δ/Δ mutant (C), and isogenic control strain (D) was 
determined as OD600nm and expressed as a percentage of the growth in the minus drug 
(DMSO) control wells. Data from a representative experiment is shown, but similar 
results were obtained in a second repeat experiment.  
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consequences in the response of C. albicans against the most important class of 
antifungals in clinical use. 
 
 We also determined that the ability of the vps21Δ/Δ mutant to tolerate azole 
exposure is dependent upon signaling through the Ca2+-responsive phosphatase 
calcineurin. In C. albicans and other fungi, the role for Ca2+-dependent calcineurin 
signaling in the cellular response to azole antifungals has been widely described (147). 
Upregulation of calcineurin signaling enhances the survival of the fungal cell by 
expressing a multitude of genes involved in the response against membrane stressors, 
including azole antifungals (148, 242). Importantly, genetic or pharmacological inhibition 
of calcineurin signaling renders the normally static azoles into cidals (149, 150). As 
suggested by our reporter assay in Figure 4-6A, abnormal Ca2+ homeostasis could 
potentially increase the basal level of calcineurin activity and/or affect the magnitude or 
duration of calcineurin signaling in the vps21Δ/Δ mutant upon azole exposure. This in 
turn may increase the chances of the mutant’s survival by, for example, minimizing the 
deleterious effects of azole treatment upon plasma membrane integrity. Consequently, it 
was not surprising that inhibition of calcineurin signaling with CsA or FK506 rendered 
the vps21Δ/Δ mutant susceptible to fluconazole. Interestingly, previous studies showed 
that membrane trafficking mutants of C. albicans defective in endosome-to-Golgi 
retrograde transport have constitutive activation of calcineurin signaling and enhanced 
expression of genes involved in stress responses (222). However, these mutants were 
hypersensitive to azole treatment. Collectively, these findings suggest that the specific 
PVC trafficking step affected is a crucial determinant of the physiological impact of the 
azoles upon the fungal cell. 
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CHAPTER 5.    THE CANDIDA ALBICANS MUTANT LACKING THE RAB 
GTPASE VPS21P IS SUSCEPTIBLE TO AZOLE TREATMENT IN VIVO 
 
 
Introduction 
 
 In previous chapters we showed that the C. albicans vps21Δ/Δ mutant defective in 
trafficking through the PVC is tolerant to azole exposure under standard susceptibility 
testing conditions. This tolerance phenotype resembled the “trailing growth” 
phenomenon that is observed in a small percentage of clinical isolates of C. albicans, 
whereby an isolate that appears susceptible to azole treatment at 24 hours, is capable of 
continued growth and seemingly resistant at the 48 hour time-point (143, 144). We also 
determined that the tolerance of the vps21Δ/Δ mutant to azole antifungals is dependent 
upon Ca2+ and calcineurin signaling. 
 
 The contribution of several mechanisms of azole resistance, such as 
overexpression of the target enzyme Erg11p and/or efflux pumps Cdr1p and Mdr1p, to 
the trailing growth phenomenon has been investigated (123). However, their role as 
causative of this form of azole tolerance has not been conclusive. Although “trailing 
isolates” are capable of tolerating azole exposure in vitro, they appear to be susceptible 
when exposed to azoles in mouse models of disseminated C. albicans infection (143, 
144). However, the possible interactions between azole resistance mechanisms and the 
trailing growth phenomenon have not been explored, in part due to the fact that the 
molecular mechanisms responsible for the trailing growth phenomenon have not been 
completely defined. The objective of the studies described in this chapter was to define 
whether defective endosomal trafficking synergizes or antagonizes with known azole 
resistance mechanisms. In addition, we sought to determine if the azole tolerance of the 
vps21Δ/Δ mutant affects the in vivo antifungal efficacy of the azoles. 
 
 
Materials and Methods 
 
 
Growth and media conditions 
 
 C. albicans was routinely grown in YPD medium (1% yeast extract, 2% peptone, 
2% dextrose) at 30°C, supplemented with uridine (50 μg/mL) when necessary. 
Transformant selection was carried out on minimal YNB medium (6.75 g/L yeast 
nitrogen base without amino acids, 2% dextrose, 2% Bacto agar), supplemented with the 
appropriate auxotrophic requirements as described for S. cerevisiae (185) or 50 μg/mL 
uridine. 
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Plasmid construction 
 
 All oligonucleotides used in this study are listed in Table 5-1. Plasmid pKE1 was 
previously described (187). Plasmid pKE4 was constructed by replacing the ACT1 
promoter from pKE1 with the TEF1 promoter which was amplified with primers 
TEF1pF-KpnI and TEF1pR-SalI from SC5314 genomic DNA (gDNA), and cloned using 
KpnI and SalI restriction sites of pKE1. 
 
 The ERG11 ORF was amplified from SC5314 gDNA with HiFi Platinum Taq 
(Invitrogen) and primer set ERG11ORFF + ERG11ORFR, and cloned between the SalI 
and MluI restriction sites of pKE4 to produce plasmid pKE4ERG11. 
 
 Plasmid pKE4CDR1 was produced by amplifying the CDR1 ORF from SC5314 
gDNA with HiFi Platinum Taq (Invitrogen) and primer pair CDR1ORFF-SalI + 
CDR1ORFR-MluI, and then cloned between the SalI and MluI restriction sites of pKE4. 
 
 The CDR2 ORF was amplified from SC5314 gDNA with HiFi Platinum Taq 
(Invitrogen) and primer pair CDR2ORFF-SalI + CDR2ORFR-MluI, and cloned between 
the SalI and MluI restriction sites of pKE4 to produce plasmid pKE4CDR2. 
 
 For construction of the plasmid pKE4MDR1, the MDR1 ORF was amplified with 
HiFi Platinum Taq (Invitrogen) and primer pair MDR1ORFF-EagI + MDR1ORFR-MluI 
from SC5314 gDNA, and cloned between the EagI and MluI restriction sites of pKE4 to 
produce plasmid pKE4MDR1. 
 
 
C. albicans strain construction 
 
 Strains used in this study are listed in Table 5-2. Transformation of C. albicans 
with DNA constructs was performed using the lithium acetate method (217). Gene 
deletion strains were constructed by the PCR-based approach described by Wilson et al. 
(190) using the ura3Δ/Δhis1Δ/Δarg4Δ/Δ strain BWP17 (kindly provided by Dr. Aaron 
Mitchell, Carnegie Mellon University). Strain CAI4 was kindly provided by Dr. William 
Fonzi (Georgetown University). Strain SC5314 has been previously described (216). 
Control strain YJB6284 (215) was kindly provided by Dr. Judith Berman (Tel Aviv 
University). The azole resistant strain AR46606 was kindly provided by Dr. Mairi C. 
Noverr (Louisiana State University Health Sciences Center). 
 
 The vps21Δ/Δ and vps21Δ/Δura3Δ/Δ were constructed in previous studies (51). 
CAI4 and the vps21Δ/Δura3Δ/Δ were transformed with pKE4, pKE4ERG11, 
pKE4CDR1, pKE4CDR2, pKE4MDR1. Correct integration of the above plasmids fully 
restores the URA3 and adjacent IRO1 loci, and this was confirmed by PCR analysis using 
primer pair LUXINTDETF + LUXINTDETR which yields a 2199 bp product. 
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Table 5-1. List of oligonucleotides used in the study described in Chapter 5. 
 
 
Primer Sequence (5’-3’) 
CDR1ORFF-SalI  TCAGTCGACATGTCAGATTCTAAGATGTCG 
CDR1ORFR-MluI TCAACGCGTGACGTTTGAGATACCACCATGTC 
CDR2ORFF-SalI  TCAGTCGACATGAGTACTGCAAACACGTCT 
CDR2ORFR-MluI TCAACGCGTTTGTAAAATAAGACCCCATCC 
ERG11ORFF TCAGTCGACATGGCTATTGTTGAAACTGTC 
ERG11ORFR TCAACGCGTTGAATCGAAAGAAAGTTGCCG 
LUXINTDETF CTGACCTTTAGTCTTTCCTGC 
LUXINTDETR CAGTAGTACTTGTTGTTGTATCG 
MDR1ORFF-EagI TCACGGCCGATGCATTACAGATTTTTGAGAG 
MDR1ORFR-MluI TCAACGCGTATAGGAAAACAATGACACCTC 
TEF1pF-KpnI TCAGGTACCTGCAAATCTGTTTGCTGATGG 
TEF1pR-SalI TCAGTCGACGATTGATTATGACTATAATGTG 
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Table 5-2. List of strains used in the study described in Chapter 5. 
 
 
Strain Relevant Genotype Reference 
SC5314 Wild-type/clinical isolate (229) 
CAI4 ura3∆/∆ (193) 
BWP17 ura3∆/∆ his1∆/∆ arg4∆/∆ (190) 
YJB6284 ura3∆/∆:URA3 his1∆/∆:HIS1 arg4∆/∆:ARG4 (215) 
AR46606 Azole resistant clinical isolate Noverr Lab 
vps21∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4 (51) 
vps21∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4  (51) 
CAI4 + TEF1prERG11 ura3∆/∆:URA3:TEF1prERG11 ERG11/ERG11 This study 
vps21∆/∆ + TEF1prERG11 ura3∆/∆:URA3:TEF1prERG11 his1∆/∆ arg4∆/∆ 
vps21∆:HIS1/vps21∆:ARG4 ERG11/ERG11 
This study 
CAI4 + TEF1prCDR1 ura3∆/∆:URA3:TEF1prCDR1 CDR1/CDR1 This study 
vps21∆/∆ + TEF1prCDR1 ura3∆/∆:URA3:TEF1prCDR1 his1∆/∆ arg4∆/∆ 
vps21∆:HIS1/vps21∆:ARG4 CDR1/CDR1 
This study 
CAI4 + TEF1prCDR2 ura3∆/∆:URA3:TEF1prCDR2 CDR2/CDR2 This study 
vps21∆/∆ + TEF1prCDR2 ura3∆/∆:URA3:TEF1prCDR2 his1∆/∆ arg4∆/∆ 
vps21∆:HIS1/vps21∆:ARG4 CDR2/CDR2 
This study 
CAI4 + TEF1prMDR1 ura3∆/∆:URA3:TEF1prMDR1 MDR1/MDR1 This study 
vps21∆/∆ + TEF1prMDR1 ura3∆/∆:URA3:TEF1prMDR1 his1∆/∆ arg4∆/∆ 
vps21∆:HIS1/vps21∆:ARG4 MDR1/MDR1 
This study 
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Antifungal susceptibility testing 
 
 Antifungal susceptibility testing of all the strains was performed using the broth 
micro-dilution method described in the CLSI document M27-A3 (218) in a 96-well plate 
format. Fluconazole was diluted in DMSO in 2-fold dilutions at 200 times the final 
concentration. RPMI 1640 medium (Sigma-Aldrich) was prepared according to the CLSI 
document (218), and the medium was buffered with morpholinepropanesulfonic acid 
(MOPS) and pH adjusted to 7.0 using NaOH. Plates were incubated without shaking at 
35°C for 24 or 48 hours unless otherwise stated. The content of each well was carefully 
resuspended by pipetting up and down before OD600nm was measured using a Cytation™ 
5 plate reader (BioTek Instruments, Inc.). 
 
 
Mouse model of vaginal candidiasis and treatment of the vps21Δ/Δ mutant with 
fluconazole in vivo 
 
 The murine model of Candida vaginitis has been reported extensively in the 
literature and was performed as described previously (246). The animals used in this 
study were housed in AAALAC-approved facilities located at the Louisiana State 
University Health Sciences Center (LSUHSC) in the School of Dentistry. The LSUHSC 
Animal Care and Use Committee approved all animals and protocols. Mice were given 
standard rodent chow and water ad libitum. Mice were monitored daily for signs of 
distress, including noticeable weight loss and lethargy. C57BL/6 mice were purchased 
from Jackson Laboratories and housed in isolator cages mounted onto ventilated racks. 
Mice were administered 0.1 mg of estrogen (β-estradiol 17-valerate; Sigma) dissolved in 
0.1 mL sesame oil subcutaneously 72 hours prior to inoculation with C. albicans. 
Estrogen injections were administered weekly thereafter. Stationary-phase cultures of C. 
albicans isolates were washed three times in sterile, endotoxin-free phosphate-buffered 
saline (PBS) and resuspended in a 0.2X volume of PBS. Cell suspensions were diluted, 
counted on a Neubauer hemocytometer, and adjusted to 2.5 × 108 CFU mL-1 in sterile 
PBS. Estrogen-treated mice were intravaginally inoculated with 20 μL of the 
standardized cell suspension, generating an inoculum size of 5 × 106 blastoconidia. 
Animals were infected with the following strains: SC5314 (WT), the vps21Δ/Δ mutant, 
the complemented strain (vps21Δ/Δ + VPS21), and the azole resistant vaginal isolate 
AR46606. For fluconazole treatment, animals infected with each strain were divided into 
two groups of five mice each. Every group was administered fluconazole at 25 mg/kg or 
vehicle at day 4 post inoculation by oral gavage. Vaginal lavage was carried out at day 7 
and 10 post inoculation to determine colony forming units (CFUs) as a measure of 
infection/clearance.  
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Results 
 
 
The C. albicans vps21Δ/Δ mutant is susceptible to azole treatment in a mouse model 
of vaginal candidiasis 
 
 Although trailing isolates are tolerant to azole treatment in vitro, in vivo studies 
conducted in mouse models of disseminated candidiasis suggest that such isolates are 
susceptible to azole treatment in vivo (143, 144). In order to determine whether the 
vps21Δ/Δ mutant is susceptible or tolerant to azole treatment in vivo, and to establish the 
clinical significance of endosomal trafficking with respect to azole tolerance, we tested 
the vps21Δ/Δ mutant’s response to fluconazole treatment in a mouse model of vaginal 
candidiasis. Mice were treated with estrogen in order to establish and maintain C. 
albicans infection. After 4 days post-infection, animals were treated with 25 μg/mL of 
fluconazole or vehicle, and clearance was determined as CFU from vaginal lavage at day 
7 and 10. 
 
 The vps21Δ/Δ mutant was able to colonize the mouse vagina at levels similar to 
the control strains, as indicated by the CFUs of untreated animals at day 7 and 10 post 
infection (Figure 5-1A and B). Treatment with fluconazole reduced the CFUs of the 
vps21Δ/Δ mutant at day 7 and to a lesser degree at day 10 post infection (Figure 5-1A), 
to a similar extent to that observed in the susceptible VPS21+ control strains. This 
suggests that the vps21Δ/Δ mutant is susceptible to azole treatment in vivo, like the 
susceptible control strains. Thus, the vps21Δ/Δ mutant’s azole tolerance in vitro does not 
seem to translate into reduced susceptibility in vivo or increased fungal persistence upon 
azole treatment in the mouse vagina. 
 
 
Overexpression of ERG11 antagonizes azole tolerance in the C. albicans vps21Δ/Δ 
mutant 
 
 The need to explore the role of trailing growth in the development of azole 
resistance has been suggested previously (123). Azole resistance mechanisms such as 
overexpression of ERG11 as well as CDR1, CDR2 and MDR1, and amino acid 
substitutions in Erg11p have been described in a multitude of azole resistant clinical 
isolates of C. albicans (81). However, a combination of these mechanisms is usually 
required to confer high levels of azole resistance (125). Moreover, there are a number of 
resistant clinical isolates in which no known mechanisms of azole resistance have been 
identified. Therefore we aimed to determine whether deficient endosomal trafficking may 
synergize or antagonize with known azole resistance mechanisms in C. albicans. To 
address this, we overexpressed the genes encoding for the target enzyme ERG11, and the 
efflux pumps CDR1, CDR2, and MDR1 from the TEF1 promoter in the vps21Δ/Δ mutant 
and tested the susceptibility of the “overexpressor” strains to fluconazole.  
 
 Overexpression of the genes encoding the efflux pumps did not significantly 
affect the tolerance to fluconazole of the vps21Δ/Δ (Figure 5-2A-C), indicating that   
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Figure 5-1. The C. albicans vps21Δ/Δ mutant is susceptible to azole treatment in a 
mouse model of vaginal candidiasis.
The susceptibility to fluconazole of the WT (SC5314), vps21Δ/Δ mutant, complemented 
control strain and the azole resistant clinical isolate AR46606 was compared in a mouse 
model of vaginal candidiasis. For each strain tested, groups of four animals were treated 
with 25 μg/mL of fluconazole or vehicle by oral gavage at 4 days post-infection (p.i.). 
Clearance/infection was determined as colony forming units (CFU) from vaginal lavage 
carried out at day (A) 7 and (B) 10 p.i. 
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Figure 5-2. Overexpression of efflux pumps does not synergize or antagonize 
azole tolerance in the C. albicans vps21Δ/Δ mutant. 
The genes encoding for the efflux pumps Mdr1p (A), Cdr1p (B), and Cdr2p were 
expressed from the TEF1 promoter in CAI4 (WT) and vps21Δ/Δ mutant. The 
susceptibility to fluconazole of the overexpressing and control strains was compared 
using the standard CLSI broth microdilution protocol. Following 48 hours incubation, 
growth was measured as OD600nm and expressed as a percentage of the growth in the 
minus drug (DMSO alone) control wells. The means ± standard deviations of two 
biological replicates are shown. 
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overexpression of efflux pumps does not synergize or antagonize with endosomal 
trafficking. Importantly, overexpression of CDR1 in the vps21Δ/Δ mutant negatively 
affected the growth of the resulting strain in the control wells (no drug), but not in the 
presence of fluconazole as determined by OD600nm (data not shown). Therefore it seems 
apparent that in the presence of fluconazole, the percentage growth of the vps21Δ/Δ 
mutant overexpressing CDR1 is elevated with respect to the vps21Δ/Δ control strain, 
although the OD600nm are similar (data not shown).  
 
 Interestingly, overexpression of ERG11 significantly reduced the fluconazole 
tolerance at the 48 hour time point, despite increasing the MIC of the mutant by 24 hours 
(Figure 5-3A and B). These suggests that overexpression of ERG11 antagonizes azole 
tolerance dependent on altered endosomal trafficking. 
 
 
Discussion 
 
 Thus far we have determined that the C. albicans vps21Δ/Δ mutant tolerates azole 
exposure, and this ability depends upon both Ca2+ and calcineurin signaling. Furthermore, 
we determined that the pattern of growth of the mutant in the presence of azoles 
resembled that of “trailing” isolates of C. albicans. In order to determine the clinical 
relevance of these findings, we studied possible interactions between azole tolerance as a 
result of loss of Vps21p-mediated trafficking through the PVC and known azole 
resistance mechanisms. No synergism or antagonism seems to occur between loss of 
Vps21p and overexpression of genes encoding for the efflux pumps Cdr1p, Cdr2p and 
Mdr1p. However, we found an antagonistic relationship between deletion of VPS21 and 
overexpression of the gene encoding the azoles target enzyme Erg11p. Overexpression of 
ERG11 increased the MIC in both vps21Δ/Δ mutant and wild-type after 24 hours 
incubation, but it reduced the tolerance of the mutant at the 48 hour time point. This is 
interesting, since in Chapter 3 we showed that the tolerance phenotype of the vps21Δ/Δ 
mutant was dependent upon Erg11p inhibition, reflecting a complex interaction between 
the expression of Erg11p and disruption of endosomal trafficking mediated by Vps21p. 
 
 We also tested the susceptibility of the vps21Δ/Δ mutant to azole treatment in vivo 
using a mouse model of vaginal candidiasis. We selected this model based on several 
considerations. First, the vps21Δ/Δ mutant has been shown to have reduced virulence in a 
mouse model of disseminated candidiasis, which can complicate the interpretation of 
results if the susceptibility to fluconazole is tested in this model. Secondly, the mouse 
vagina has a temperature of around 35°C and a neutral pH, similar to those used in the 
CLSI protocol for susceptibility testing. Several studies performed to date have suggested 
that the trailing growth phenotype is usually associated with in vivo susceptibility to azole 
therapy (143, 144). In this context, we determined that our vps21Δ/Δ mutant was 
susceptible to azole treatment in vivo in a mouse model of vaginal candidiasis. These 
susceptibility results are analogous to those obtained for clinical trailing isolates in mouse 
models of disseminated candidiasis (143, 144). However, whether or not endosomal 
trafficking defects contribute to the trailing growth phenomenon in clinical isolates is a   
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Figure 5-3. Overexpression of ERG11 reduces azole tolerance in the C. albicans 
vps21Δ/Δ mutant. 
The ERG11 ORF was expressed from the TEF1 promoter in CAI4 (WT) and vps21Δ/Δ 
mutant. The susceptibility to fluconazole of the ERG11-overexpressing and control 
strains was evaluated using the standard CLSI broth microdilution protocol. Following 24 
(A) and 48 hours (B) incubation, growth was measured as OD600nm and expressed as a 
percentage of the growth in the minus drug (DMSO alone) control wells. The mean ± 
standard deviations of two biological replicates are shown. The means of each group 
were compared using a two-tailed t-test. * P < 0.05, between the vps21Δ/Δ mutant and 
vps21Δ/Δ + TEF1prERG11 strain. 
  
 90 
matter that has not been explored to date. 
 
 Collectively, these findings highlight the importance of Vps21p-mediated 
trafficking in determining the outcome of azole treatment in C. albicans both in vitro and 
in vivo. 
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CHAPTER 6.    DISCUSSION† 
 
 
Azole Antifungals and Vacuolar Integrity 
 
 The fungal lipid ergosterol is a major membrane component that plays key roles 
in supporting plasma membrane function and integrity (79, 80). It has been implicated in 
processes that include endocytosis, homotypic vacuole fusion, pheromone signaling and 
the function of several proteins (81, 82, 169, 170). The importance of ergosterol is such, 
that a number of antifungal drugs target its biosynthesis. The most important class of 
antifungals currently in clinical use is the azoles. They prevent the synthesis of ergosterol 
by inhibiting the enzyme lanosterol 14-demethylase (Erg11p). In addition, inhibition of 
Erg11p leads to the accumulation of methylated sterols that ultimately insert in the 
plasma membrane and cause instability and loss of function that result in growth 
inhibition (92). Loss of plasma membrane function due to both the accumulation of toxic 
sterol species and ergosterol depletion in the plasma membrane have been widely 
acknowledged as the main antifungal mechanisms of azole antifungals (196). However, 
other intracellular membranes contain ergosterol, although in relatively smaller quantities 
(173). Therefore the integrity and function of intracellular membranes can be 
compromised due to azole treatment and inhibition of ergosterol biosynthesis. This opens 
the question of whether the antifungal activity of the azoles is only due to loss of plasma 
membrane integrity or if it is also associated with the dysfunction of intracellular 
membranes. 
 
 The vacuole is a membrane-bound compartment whose importance in stress 
responses and pathogenesis has been well defined in fungi (156, 166). In this work, we 
showed that treatment with azole antifungals severely compromise C. albicans vacuole 
integrity, and that this phenomenon is a result of Erg11p inhibition and not an off-target 
effect of azole treatment. Furthermore, vacuole disruption was shown to occur as an early 
event following drug exposure, before significant growth inhibition was observed. These 
findings support the notion that azole antifungals not only disrupt plasma membrane 
integrity but other intracellular membrane compartments are also affected. In addition to 
supporting C. albicans resistance to a multitude of different stresses, the vacuole has been 
shown to support hyphae formation and the ability of C. albicans to survive and cause 
lethality in vivo. C. albicans mutants with severe defects in vacuolar function have 
reduced growth rates, and are susceptible to multiple stresses, defective in filamentous 
growth and unable to cause lethality in a mouse model of disseminated candidiasis (49, 
51, 166). Thus it is possible that the impairment of vacuolar function as a result of azole 
exposure contributes to the antifungal activity of the azoles, in addition to the 
 
 
-------------------- 
† Modified by permission of American Society for Microbiology. Luna-Tapia A, Tournu 
H, Peters TL, Palmer GE. 2016. Endosomal trafficking defects can induce calcium 
dependent azole tolerance in Candida albicans. Antimicrob Agents Chemother 60:000 –
000. doi:10.1128/AAC.01034-16.   
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consequences on plasma membrane integrity. In this regard, recent work suggested that 
loss of ergosterol upon azole treatment affects the function of the V-ATPase responsible 
for vacuolar acidification, which is necessary for the function of hydrolytic enzymes and 
homotypic vacuole fusion (79). The function of a number of other vacuolar membrane 
proteins may also be affected by azole treatment, including amino acid exchangers, 
transporters, ion pumps and channels, among others. 
 
 Whether vacuole disruption following azole treatment is mediated by ergosterol 
depletion, by the accumulation of toxic sterol species in the membrane or a combination 
of both factors is less clear. Several methylated sterol species accumulate in the plasma 
membrane as a consequence of Erg11p inhibition and results in increased permeability, 
defective membrane fluidity, and ultimately, growth inhibition (141). Among those, 14α-
methylergosta-8,24(28)-dien- 3β,6α-diol amasses in large quantities in the plasma 
membrane in cells exposed to azoles and it is thought to play a major role in the 
mechanism of action of these antifungals (141). This sterol is a metabolic product of 
Erg3p after inhibition of ergosterol biosynthesis at the Erg11p step (81, 141). 
Interestingly, deletion of ERG3 ameliorated the impact of azole treatment on the integrity 
of the C. albicans vacuole, suggesting that the activity of Erg3p and presumably the 
production of toxic methylated sterols contribute at least in part to the deleterious effects 
of azole treatment on the integrity of the fungal vacuole. 
 
 
Vacuolar Trafficking as a Determinant of the Antifungal Efficacy of Ergosterol 
Biosynthesis Inhibitors 
 
 Another major finding of this work is the impact that vacuolar dysfunction can 
have on the antifungal efficacy of the azoles. Normal vacuolar function depends on 
several trafficking pathways (201), each contributing to different extents to processes 
such as hyphal growth, stress resistance and virulence (50, 51, 182). Due to the critical 
role of the vacuole in survival and pathogenesis of C. albicans and the extensive clinical 
use of azoles, it was of significance to evaluate how vacuolar dysfunction affects azole 
susceptibility in the context of vacuolar membrane trafficking. In this regard, we found 
that deficiency in autophagy or ALP trafficking did not cause significant changes in azole 
susceptibility. However, lack of the Rab GTPase Vps21p, which controls membrane 
fusion events at the pre-vacuolar compartment, enhanced C. albicans survival after azole 
exposure. Interestingly, Vps21p seems to not only impact fungal susceptibility to azoles 
antifungals but also other ergosterol biosynthesis inhibitors like terbinafine and 
amorolfine, which inhibit alternate steps along the ergosterol biosynthetic pathway. 
Interestingly, the effect of Vps21p on azole tolerance seems to be particular to the 
trafficking step that it mediates, since the azole tolerance phenotype was also observed in 
a pep12Δ/Δ mutant. Moreover, we also found that membrane fusion events at the 
vacuolar membrane mediated by another Rab GTPase, Ypt72p, can affect C. albicans 
susceptibility to azole antifungals, but to a lesser degree than Vps21p. This further 
highlights the importance of vacuolar function and dysfunction, and specifically vacuolar 
trafficking pathways, on the antifungal activity of the azoles and other ergosterol 
biosynthesis inhibitors.  
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 The mechanism by which the C. albicans vps21Δ/Δ mutant was tolerant to azole 
treatment, but more hypersensitive to other ergosterol biosynthesis inhibitors is not clear. 
However, by targeting alternate steps along the ergosterol biosynthetic pathway, 
treatment with each class of inhibitor creates a particular sterol profile that depends on 
the enzyme(s) being inhibited. Since intracellular sterol trafficking depends on both 
vesicle and non-vesicle mediated transport (247), disruption of a particular trafficking 
step could affect the distribution of the sterols accumulated upon drug treatment, thus 
enhancing or avoiding the effects that the buildup of a particularly toxic sterol has on the 
membranes where they are delivered. For the vps21Δ/Δ mutant, disruption of trafficking 
at the PVC could prevent the toxic sterols accumulated upon Erg11p inhibition from 
reaching the PVC itself or another target membrane for which the PVC is an intermediate 
step. However, this effect seems to be deleterious when Erg1p or Erg2p and Erg24p are 
targeted and presumably different sterols profiles are produced. 
 
 The tolerance phenotype of the vps21Δ/Δ mutant resembles the trailing growth 
phenomenon that is observed during standard azole susceptibility testing in ~18% of C. 
albicans clinical isolates (145). “Trailing” isolates appear to be susceptible to azole 
treatment at 24 hours but can appear as azole resistant strains at the 48 hour time-point 
(144). The vps21Δ/Δ mutant not only “mimicked” the 24 vs 48 hours pattern of growth 
but also displayed some other features that “trailing” clinical isolates present such as 
enhanced growth despite ergosterol depletion and elimination of the trailing phenotype in 
acidic medium or upon incubation at 25°C or 42°C (124, 143, 219, 221). Moreover, the 
vps21Δ/Δ mutant was susceptible to azole treatment in vivo, a classic feature of “trailing” 
isolates. These observations open the question of whether clinical isolates that display 
trailing growth have altered or abnormal endosomal trafficking. This question can be 
addressed by performing phenotypic analysis on trailing isolates in order to identify 
phenotypes similar to that of the vps21Δ/Δ mutant in response to stressors such as 
hypersensitivity to SDS and Congo red, delayed endocytosis (50, 51) and differential 
responses to ergosterol biosynthesis inhibitors. Nevertheless, the mechanisms underlying 
trailing growth in clinical isolates are far from being completely understood. 
 
 
Connecting the Dots: Vacuolar Trafficking, Ca2+ Homeostasis and Azole Tolerance 
 
 The relationship between Ca2+ and membrane trafficking has been previously 
recognized, exemplified by the role for Ca2+ in the early stages of vesicular trafficking 
(248) as well as in the context of endosomal membrane trafficking and yeast homotypic 
vacuole fusion (249, 250). Two important findings of this work are that disruption of 
endosomal trafficking mediated by Vps21p creates a Ca2+ homeostasis defect 
characterized by elevated levels of intracellular Ca2+, and that the tolerance of the 
vps21Δ/Δ mutant is dependent upon Ca2+ and Ca2+-dependent signaling via the 
serine/threonine protein phosphatase calcineurin. Ca2+ dependent signaling has been 
widely linked to azole tolerance in fungi (147). In addition, the vacuole is the major 
storage site of intracellular calcium in fungi and several proteins that regulate the Ca2+ 
fluxes required for calcineurin signaling are located on the vacuolar membrane (161). 
These include the Ca2+ pump Pmc1p, the Ca2+/H+ exchanger Vcx1p and the Ca2+ channel 
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Yvc1p (161). Disruption of endosomal trafficking could potentially cause abnormal 
delivery of these proteins to the vacuolar membrane, thus altering Ca2+ homeostasis and 
contributing to azoles tolerance. However, we have determined that deletion of either 
VCX1 or PMC1 (see Appendix C for a list of strains) does not affect C. albicans azole 
susceptibility or induce trailing growth under standard testing conditions (Figure 6-1A 
and B). This suggests that if defects in trafficking lead to a lack of Pmc1p or Vcx1p in the 
vacuolar membrane, they may not be sufficient to alter azole susceptibility. 
 
 Another possibility is that the mechanisms that regulate Ca2+ pumps and channels 
on the plasma membrane are affected by the trafficking defects of the vps21Δ/Δ mutant 
and, this in turn, leads to the Ca2+ homeostasis defects observed. The S. cerevisiae 
secretory pathway, responsible for the transport of a large number of plasma membrane 
and extracellular proteins, require the Ca2+ pump Pmr1p (251). Pmr1p was shown to be 
regulated by ESCRT components involved in membrane sorting at the PVC, including 
Vps28p. Mutants lacking Pmr1p or components of vesicle-mediated trafficking (161) 
exhibit higher rates of Ca2+ uptake due to constitutive activation of a high-affinity Ca2+ 
influx system (HACS) (161) formed by Cch1p and Mid1p (252), the yeast homologous of 
the mammalian L-type Ca2+ channel. Cch1p/Mid1p appear to ensure the uptake of Ca2+ 
needed by Pmr1p to sustain the secretory pathway (252). Thus, alterations in PVC 
membrane trafficking could potentially alter Ca2+ homeostasis via several mechanisms. 
Although we did not establish the mechanism responsible for the increased levels of 
cytoplasmic Ca2+ in the mutant, we found that the adjunctive treatment with Ca2+ channel 
blocker nisoldipine rendered the vps21Δ/Δ mutant sensitive to fluconazole. These results 
highlight the need of the mutant for an active Ca2+ channel in order tolerate azole 
treatment, presumably Cch1p/Mid1p. 
 
 We also found that calcineurin dependent gene expression in the vps21Δ/Δ mutant 
appears to be enhanced upon azole exposure, as indicated by the reporter assay using 
GFPγ under the promoter of the calcineurin responsive gene RTA2. As expected, 
inhibition of calcineurin signaling with CsA or FK506 rendered the vps21Δ/Δ mutant 
susceptible to fluconazole. The role of calcineurin signaling in the mutant’s azole 
tolerance could be explained in the models outlined in Figure 6-2 and Figure 6-3. In a 
“wild-type” strain (Figure 6-2), azole treatment (step 1) causes a release of Ca2+ from 
intracellular stores and influx from the medium (step 2). This in turn leads to activation of 
calcineurin signaling (step 3), followed by dephosphorylation of a calcineurin-dependent 
transcription factor such as Crz1p (step 4) and the expression of genes involved in stress 
response (step 5) and azole tolerance (step 6).  
 
 In the vps21Δ/Δ mutant (Figure 6-3): disruption of Vps21p-mediated trafficking 
(step 1) creates a calcium homeostasis defect (i.e., elevated basal levels of cytoplasmic 
Ca2+) that may rely on a plasma membrane channel (perhaps Cch1p/Mid1p, step 2). This 
may affect the basal level of calcineurin activity and/or affect the magnitude or duration 
of calcineurin signaling (step 3) and downstream events (step 4). This could lead to 
enhanced expression of genes involved in stress response (step 5), which promote the 
mutant’s survival (step 6) once it is exposed to azole antifungals (step 7).  
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Figure 6-1. The vacuolar calcium pump Pmc1p and the Ca2+/H+ exchanger Vcx1p 
do not impact C. albicans susceptibility to fluconazole. 
The susceptibility to fluconazole of the C. albicans vcx1Δ/Δ (A) and pmc1Δ/Δ mutants 
(B) were compared to WT (YJB6284), and ‘reconstituted’ control strain using the 
standard CLSI broth microdilution protocol. Growth is expressed as a percentage of the 
growth in the minus drug (DMSO) control wells. The means ± standard deviation of two 
biological replicates is shown for each panel. 
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Figure 6-2. Accepted model of Ca2+ dependent response to azole antifungals in C. 
albicans. 
Azole exposure (1) induces rapid fluxes of Ca2+ from the extracellular space and its 
release from intracellular stores into the cytoplasma (2). The elevated Ca2+ levels allow 
activation of the calcineurin signaling pathway (3 and 4) and the expression of number of 
genes (5) involved in stress response (5) and survival to azoles (6). 
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Figure 6-3. Proposed model for the Ca2+ dependent azole tolerance in the C. 
albicans vps21Δ/Δ mutant. 
Disruption of membrane trafficking mediated by the Rab GTPase Vps21p (1) causes a 
Ca2+ homeostasis defect (2) represented by elevated levels of intracellular Ca2+ that may 
alter the intensity of calcineurin activity (3). Calcineurin-dependent transcription factors 
(4) then drive the enhanced expression of genes involved in stress responses (5) that 
support the survival of the vps21Δ/Δ mutant upon azole exposure (6 and 7). 
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 Although loss of Vps28p, an ESCRT component involved in MVB biogenesis at 
the PVC, affects Ca2+ homeostasis leading to activation of calcineurin signaling in S. 
cerevisiae, our results indicate that Vps28p does not impact azole tolerance in C. 
albicans. Furthermore, it was previously reported that a C. albicans mutant defective in 
retrograde trafficking from the PVC back to the Golgi is highly sensitive to the azoles 
despite having upregulated calcineurin signaling (222). Taken together, these findings 
indicate that azole tolerance in membrane trafficking mutants does not only depend on 
activation of calcineurin signaling, but it is also determined by the trafficking steps 
blocked. In support of this notion deletion of APS3 (see Appendix C for a list of strains), 
which controls trafficking through the ALP pathway, abolished the C. albicans vps21Δ/Δ 
mutant’s ability to withstand azole exposure (Figure 6-4) despite having no effect on the 
susceptibility of the “wild-type” (Figure 3-2B). Thus, the vps21Δ/Δ mutant’s azole 
tolerance is not only dependent on Ca2+ and calcineurin signaling, but also relies on 
membrane trafficking, specifically from the Golgi to the vacuole. This further highlights 
the significance of membrane trafficking in the antifungal activity of azole antifungals in 
C. albicans. 
 
 
Concluding Remarks 
 
 The work described herein revealed that a C. albicans vps21Δ/Δ mutant displays 
enhanced growth in response to azole treatment, resembling an exaggerated form of the 
trailing growth phenomenon. However, it is unclear how, or if the azole tolerant 
phenotype of the vps21Δ/Δ mutant relates to that of trailing clinical isolates, or if these 
clinical isolates have abnormal endosomal trafficking. This could be investigated by 
testing trailing clinical isolates for phenotypes indicative of endosomal trafficking 
defects. This would include sensitivity to SDS, Congo red, allylamines and morpholines, 
and delayed endocytosis (50, 51, 186). 
 
 While deletion of VPS21 alone was not sufficient to confer a survival advantage 
upon C. albicans following azole treatment in the mouse model of vaginal candidiasis, 
several important questions remain. First, the azole susceptibility of the vps21Δ/Δ mutant 
could be tested in a mouse model disseminated infection. This may be important because 
several C. albicans mutants that are avirulent in the disseminated model have no apparent 
defects in pathogenicity in the vaginal model of infection. For example, we have recently 
reported that C. albicans lacking ERG2 or ERG24, which encode enzymes involved in 
ergosterol biosynthesis, are pathogenic in a mouse model of vaginal infection but not in 
the mouse model of disseminated candidiasis (172). Second, as the fungistatic azoles 
depend upon the host’s immune defenses to clear fungal infections, it will be important to 
determine if the C. albicans vps21Δ/Δ mutant have a survival advantage over the wild-
type following azole treatment in immunocompromised hosts. This can be tested by 
conducting similar experiments to those described herein but using immunosuppressed 
mice. Third, it is crucial to determine if cells that persist following azole exposure, such 
as the vps21Δ/Δ mutant and trailing isolates, are more predisposed to develop azole 
resistance overtime. This can be tested by exposing both wild-type and vps21Δ/Δ mutant 
or trailing isolates to increasing concentrations of azole antifungals and comparing the 
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frequency of appearance of azole resistance in each passage. Finally, it was also revealed 
that the C. albicans vps21Δ/Δ mutant has elevated basal levels of Ca2+ and enhanced 
calcineurin-dependent transcriptional response following azole exposure. It will also be 
important to determine if differences in basal levels of intracellular free Ca2+ and azole-
induced Ca2+-dependent signaling contribute to variations in azole susceptibility in 
clinical isolates. This can be tested by using several of the methodologies described in 
this work. 
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Figure 6-4. Disruption of the ALP trafficking pathway in the C. albicans vps21Δ/Δ 
mutant eliminates azole tolerance. 
The susceptibility to fluconazole of the vps21Δ/Δaps3Δ/Δ double mutant was compared 
to that of the vps21Δ/Δ mutant, aps3Δ/Δ, YJB6284 (WT), and ‘reconstituted’ control 
strains using the standard CLSI broth microdilution protocol. Growth was measured as 
OD600nm and expressed as a percentage of the DMSO control wells. The mean ± 
standard deviation of two biological replicates is shown. 
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APPENDIX A. SUPPLEMENTAL FIGURES FOR CHAPTER 3 
 
 
Figure A-1. The C. albicans Vps21p paralogs Ypt52p and Ypt53p do not 
significantly affect susceptibility to miconazole. 
(A-C) The susceptibility of C. albicans ypt52Δ/Δ (A), ypt53Δ/Δ (B), and 
ypt52Δ/Δypt53Δ/Δ (C) mutants to miconazole was tested using the standard CLSI broth 
microdilution protocol. After 48 hours incubation, growth was measured as OD600nm and 
expressed as a percentage of the growth in the minus drug (DMSO alone) control wells. 
(D-F) The susceptibility of C. albicans ypt52Δ/Δypt53Δ/Δ (D), vps21Δ/Δypt52Δ/Δ (E) 
and vps21Δ/Δypt53Δ/Δ (F) double mutants was tested as described above. The mean of at 
least two independent experimental replicates is shown for all panels. 
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Figure A-2. Deletion of VPS28 does not affect C. albicans susceptibility to 
fluconazole. 
The susceptibility of the C. albicans vps28Δ/Δ mutant and control strains to fluconazole 
was evaluated using the standard CLSI broth microdilution protocol. After 48 hours 
incubation, growth was measured as OD600nm and expressed as a percentage of the growth 
in the minus drug (DMSO alone) control wells. The means ± standard deviations of three 
biological replicates are shown. 
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Figure A-3. The composition of sterols extracted from fluconazole-treated 
vps21Δ/Δ mutant is similar to that of the isogenic control. 
The C. albicans vps21Δ/Δ mutant and its isogenic control strain were grown in YNB 
broth with 4 µg/mL fluconazole (A and B top panel) or 0.5% DMSO (A and B bottom 
panel) for 24 hours at 35°C, total cellular sterols extracted using n-heptane and analyzed 
by NMR analysis. 
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APPENDIX B. SUPPLEMENTAL FIGURES FOR CHAPTER 4 
 
 
 
Figure B-1. Fluconazole induced expression of GFP from the RTA2 promoter is 
calcineurin dependent. 
The RTA2pr-GFPγ expression construct was introduced into C. albicans strain CAI4, and 
the resulting strain cultured in YNB medium with either 1 µg/mL fluconazole (FLU), 2 
µg/mL cyclosporine A (CsA), a combination of both drugs, or 0.5% DMSO. Cells were 
incubated for 24 hours at 30ºC. Fluorescence intensity was determined by excitation at 
488 nm and emission at 507 nm, normalized for cell density (OD600nm), and expressed as 
relative fluorescence units (RFU). The mean ± standard deviation of two biological 
replicates is shown. A two-tailed t-test was used to compare the mean of each group; * P 
< 0.006. 
  
 122 
 
Figure B-2. The calcineurin signaling inhibitor FK506 eliminates the C. albicans 
vps21Δ/Δ mutant’s azole tolerance. 
The effect of calcineurin signaling inhibition with FK506 on azole tolerance in the WT 
(A), vps21Δ/Δ mutant (B) and isogenic control strain (C) was evaluated using a 
checkerboard assay using the standard CLSI broth microdilution protocol. Growth was 
determined as a percentage of the minus drug (DMSO) control. A representative 
experiment is shown, but similar results were obtained in a second repeat experiment. 
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APPENDIX C. LIST OF STRAINS DESCRIBED IN CHAPTER 6 
 
 
 
Strain Relevant Genotype Reference 
YJB6284 ura3∆/∆:URA3 his1∆/∆:HIS1 arg4∆/∆:ARG4 (215) 
vps21∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4 (51) 
vps21∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:ARG4  (51) 
aps3∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ aps3∆:HIS1/aps3∆:ARG4 (50) 
aps3∆/∆ + APS3 ura3∆/∆:URA3:APS3 his1∆/∆ arg4∆/∆ aps3∆:HIS1/aps3∆:ARG4 (50) 
vps21∆/∆aps3∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
aps3∆:ARG4/aps3∆:dpl200 
(50) 
vps21∆/∆aps3∆/∆ + VPS21 ura3∆/∆:URA3:VPS21 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
aps3∆:ARG4/aps3∆:dpl200 
(50) 
vps21∆/∆aps3∆/∆ + APS3 ura3∆/∆:URA3:APS3 his1∆/∆ arg4∆/∆ vps21∆:HIS1/vps21∆:dpl200 
aps3∆:ARG4/aps3∆:dpl200 
(50) 
vcx1∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ vcx1∆:HIS1/vcx1∆:ARG4 This study 
vcx1∆/∆ + VCX1 ura3∆/∆:URA3:VCX1 his1∆/∆ arg4∆/∆ vcx1∆:HIS1/vcx1∆:ARG4  This study 
pmc1∆/∆ ura3∆/∆:URA3 his1∆/∆ arg4∆/∆ pmc1∆:HIS1/pmc1∆:ARG4 This study 
pmc1∆/∆ + PMC1 ura3∆/∆:URA3:PMC1 his1∆/∆ arg4∆/∆ pmc1∆:HIS1/pmc1∆:ARG4  This study 
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